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1. Abstract 
 
Death-associated protein kinase (DAPK) is a serine/threonine kinase that contributes 
to pro-apoptotic signalling upon cytokine exposure. Recently, it has been found that a 
high DAPK expression in colorectal tumor cells and tumor-associated macrophages 
(TAMs) was correlated with a high apoptotic rate in tumor cells but not in TAMs 
suggesting a new function of DAPK in apoptosis induction during the interaction 
between colorectal tumor cells and TAMs. However, the role of DAPK regulation in 
macrophage-associated tumor cell death is still elusive. We used a cell-culture model 
with conditioned supernatants of differentiated/activated macrophages (U937) and 
HCT116 colorectal tumor cells to recapitulate DAPK-associated tumor cell death that 
might reflect the in vivo tumor setting. We measured Cytokines in 
differentiated/activated macrophage supernatants ELISA. DAPK expression and 
DAPK activity were determined by real-time RT-PCR, Western Blotting, and DAPK in 
vitro kinase assay. Co-immunoprecipitation and triple immunofluorescence labelling 
were used to show protein interactions. For detection of protein-dependent apoptosis 
induction, we used the Annexin V-binding assay, caspase 3/7 activity ELISA, 
Western Blotting and siRNA-transfection. Here, we show that in vitro DAPK induction 
and apoptosis in tumor cells was due to TNF-α release from the activated 
macrophages. p53 was found to act down-stream of DAPK in this scenario. 
Simultaneously, an early phosphorylation of p38 MAPK was observed. We identified 
for the first time that p-p38 MAPK co-localizes and interacts with DAPK and triggers 
DAPK-mediated apoptosis in the HCT116 cells. We addressed the physiological 
relevance of our findings and showed that supernatants of freshly isolated human 
macrophages were also able to induce DAPK, p-p38, and caspase 3 cleavage in 
HCT116 cells. We further verified the co-localization of DAPK and p-p38 proteins by 
immunohistochemistry analysis of human colon cancer slices. Moreover, the 
observed apoptosis resistance in the macrophages was mediated by DAPK. Finally, 
we suggest that, the cytoprotective effect of DAPK impacts the mitochondrial 
signalling pathway by inhibiting the caspase 3 cleavage. 
Altogether, we are the first to show p-p38 triggering of DAPK-activation in TNFα-
induced apoptosis. Our findings highlight the mechanisms underlying DAPK 
regulation in tumor cell death evoked by immune cells. 
Zusammenfassung 
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2. Zusammenfassung 
 
Die death-associated protein kinase (DAPK) ist eine Ca2+/Calmodulin regulierte 
Serin-Threonin-Kinase, die nach Zytokinstimulation eine proapoptotische Funktion 
hat. Neuesten Berichten zufolge exprimieren nicht nur kolorektale Tumorzellen 
sondern auch die sie umgebenden tumor-assozierten Makrophagen die DAPK. 
Dabei war eine erhöhte DAPK-Expression in den Tumorzellen mit einer verstärkten 
Apoptose assoziiert, während DAPK-positive Makrophagen keine TUNEL-Färbung 
zeigten. Über die Rolle der DAPK bei der immunzell-vermittelten Apoptose ist bisher 
jedoch nichts bekannt. 
Um die in vivo Bedingungen zu simulieren und die DAPK-assozierte Tumorzell-
Apoptose näher zu untersuchen, wurde ein Zellkulturmodell mit konditionierten 
Überständen der ausdifferenzierten/aktivierten Makrophagen (U937) und der 
kolorektalen Tumor-Zelllinie HCT116 verwendet. Gleichzeitig sollte geprüft werden, 
ob die DAPK eine Rolle bei der Apoptoseresistenz der Makrophagen spielt. 
Zunächst wurden die in den Überständen von ausdifferenzierten/aktivierten 
Makrophagen enthaltenen Zytokine mittels ELISAs gemessen. Die DAPK-Expression 
und die DAPK-Aktivität wurden über real-time RT-PCR, Western Bloting und DAPK 
in-vitro Kinase-Assay untersucht. Die Methoden der Co-Immunopräzipitation und der 
Dreifach-Immunfluoreszenzfärbung wurden verwendet, um Protein-Protein-
Interaktionen nachzuweisen. Der Annexin V-binding Assay, die Caspase 3 und 7 
Aktivitäts-ELISAs, der Nachweis von aktiven Spaltprodukten im Western Blot sowie 
die siRNA-Transfektion wurden verwendet, um eine DAPK-abhängige 
Apoptoseinduktion zu untersuchen. Wir konnten zeigen, dass in-vitro die DAPK- 
Regulation und die Apoptoseinduktion in den Tumorzellen von der TNFα-Freisetzung 
der aktivierten Makrophagen abhängig sind. Weiterhin stellte sich heraus, dass p53 
dabei downstream von DAPK agierte. Gleichzeitig wurde eine frühe 
Phosphorylierung von p38-MAPK beobachtet. Wir konnten erstmalig die Co-
Lokalisation und Interaktion von p-p38-MAPK mit DAPK in den HCT116-Zellen nach 
TNFα-Behandlung beschreiben. Ferner induziert p-p38 die katalytische Aktivierung 
der DAPK und vermittelt somit die DAPK-abhängige Apoptose. Um die 
physiologische Relevanz unserer Daten zu zeigen, untersuchten wir das DAPK- und 
Zusammenfassung 
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p-p38-Expressionsmuster in humanen Normal-Gewebe und Gewebe von 
Kolonkarzinomen. Die immunhistochemische Analyse zeigte nur in den Tumoren 
eine DAPK-p-p38 Co-lokalisation. Auch frisch isolierte humane Makrophagen 
vermögen nach Akivierung den apopotischen Zelltod in der HCT116 Zellinie 
auszulösen. Ferner stellten wir fest, dass die beobachtete Apoptoseresistenz in den 
Makrophagen DAPK-abhängig war. Schließlich postulieren wir, dass die DAPK-
vermittelten Resistenz in den Makrophagen über den Caspase 3 Weg realisiert ist. 
Zusammenfassend zeigte unsere Studie erstmalig, dass die TNFα-induzierte 
Apoptose über eine DAPK-Aktivierung durch p-p38 ausgelöst wird. Unsere  
Ergebnisse haben eine weitreichende Bedeutung für die Erklärung der durch 
Immunzellen ausgelösten Tumorzellapoptose sowie einer Termination der 
Makrophagenantwort.  
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3.1 Protein kinases 
A protein kinase is a kinase enzyme that modifies other proteins by chemically 
adding phosphate groups to them (phosphorylation). This class of proteins is further 
separated into subsets such as PKC alpha, PKC beta, and PKC gamma, each with 
specific functions. Phosphorylation usually results in a functional change of the target 
protein (substrate) by changing enzyme activity, cellular location, or association with 
other proteins. Up to 30% of all proteins may be modified by kinase activity, and 
kinases are known to regulate the majority of cellular pathways, especially those 
involved in signal transduction, the transmission of signals within the cell. The human 
genome contains about 500 protein kinase genes; they constitute about 2% of all 
eukaryotic genes. The chemical activity of a kinase involves removing a phosphate 
group from ATP and covalently attaching it to one of three amino acids that have a 
free hydroxyl group. Most kinases act on both serine and threonine, others act on 
tyrosine, and a number (dual specificity kinases) act on all three. Because protein 
kinases have profound effects on a cell, their activity is highly regulated. Kinases are 
turned on or off by phosphorylation (sometimes by the kinase itself - cis-
phosphorylation/autophosphorylation), by binding of activator proteins or inhibitor 
proteins, or small molecules, or by controlling their location in the cell relative to their 
substrates (Anderson et al., 1990, Keranen et al., 1995, and Konishi et al., 1997). 
Disregulated kinase activity is a frequent cause of disease, particularly cancer, where 
kinases regulate many aspects that control cell growth, movement and death 
(Pawson et al., 2000).  
 
3.1.1 DAPK family 
Death-associated protein kinase1 (DAPK) is a calmodulin (CaM)-regulated 
serine/threonine protein kinase. DAPK features a multidomain structure (Fig. 1), 
comprising eight ankyrin repeats (a 33-amino acid repeat that has been implicated in 
mediating protein−protein interactions), P-loops (a mononucleotide-binding sequence 
motif), a cytoskeleton-binding region, a death-domain and a catalytic (kinase) domain 
(Cohen et al., 1997; Kimchi et al., 1998; Cohen et al., 1999; Raveh et al., 2000) that 
has high sequence similarity to vertebrate myosin light chain kinase (MLCK). Like 
MLCK, DAPK does not require phosphorylation for activation. 
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FIG. 1. Schematic diagram of DAP-kinase1 protein structure. The 160 kDa 
Ca2+/calmodulin (CaM)-regulated Ser/Thr kinase bears a multiple domain structure. 
The catalytic and the calmodulin regulatory domains determine substrate specificity 
and regulation of kinase catalytic activity, respectively. The non-catalytic association 
domains, involved in subcellular localization or interactions with other proteins, 
include the ankyrin repeats, two nucleotide-binding P-loops, a cytoskeleton-binding 
region, and a death domain.  
 
 
Four additional kinases that show a significant homology in their catalytic domain to 
DAPK have been recently identified (Inbal et al., 2000). ZIP(Dlk)-kinase and DRP-1 
are the closest family members, as their catalytic domains share approximately 80% 
identity to that of DAPK. Two more distant DAPK-related proteins are DRAK1 and 
DRAK2 (Fig. 2). Phylogenetic analyses, based on multiple sequence alignment of the 
catalytic domains of 16 proteins, show that DAPK, ZIP(Dlk)-kinase and DRP-1 may 
be grouped into a distinct clade with high bootstrap probabilities. DRAK1 and DRAK2 
form another clade sharing a putative common ancestor to the other DAPK related 
proteins. Interestingly, the extracatalytic domains of these five members differ 
considerably from each other (Fig. 2). Additionally, ZIPkinase, DRAK1 and DRAK2 
were shown to be nuclear proteins that do not require Ca2 +/CaM for activation. 
DRP-1, however, is a cytoplasmic kinase, containing a typical CaM-regulatory 
domain similar to that of DAPK and a short C-terminal segment required for 
homodimerization.(Inbal et al., 2000 and Shani et al ., 2001). Interestingly, DRP-1 
can promote cell death upon its ectopic expression and it shares with DAPK many of 
the induced subcellular events including membrane blebbing and the formation of 
autophagic vesicles (Inbal et al., 2002). 
 
 
 
Kinase Domain 
Ca2+/CaM binding 
Ankyrin repeats 
Cytoskeleton 
 binding 
Death  
Domain N C 
P-loops 
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FIG. 2. Schematic diagram of Death associated protein kinase family: DAP 
Kinase 1 (DAPK), DAP kinase related protein 1/DAP kinase 2 (DRP-1/DAPK2), DAP 
kinase 3 (DAPK3/ZIPK), DAP kinase related apoptosis inducing protein kinase 1 und 
2 (DRAK1 und DRAK2). 
 
 
3.1.1.1 DAPK function 
Death-Associated Protein Kinase1 (DAPK) is a 160 kDa-Ca2+ /Calmodulin-
dependent, cytoskeletal-associated protein kinase the expression of which is 
implicated in the sensitivity of cells to apoptotic effects of cytokines such as 
Interferon-γ, TNFα, and TGF-β (Deiss et al., 1995; Cohen et al., 1999; Jang et al., 
2001). It has been found that DAPK exerts an apoptotic effect by inside-out 
inactivation of integrin ß1, thereby suppressing the matrix survival signal and 
activating a p53-dependent apoptosis pathway (Wang et al., 2002). Accordingly, the 
proapoptotic activity of DAPK is largely dependent on the existence of functional p53 
protein, and several p53-deficient cell lines either escape from cell death (Wang et 
al., 2002) or undergo autophagic death in response to DAPK overexpression (Inbal et 
al., 2002). However, given the broad involvement of DAPK in tumor suppression and 
the frequent loss or mutation of p53 in various tumors, we postulate that DAPK elicits 
the second, apoptosis-unrelated mechanism to suppress tumor progression. Notably, 
the effects of DAPK on integrin inactivation (Wang et al., 2002) and actin 
cytoskeleton reorganization (Kuo et al., 2003; Bialik et al., 2004) raise the possibility 
of DAPK involvement in motility regulation. It has been demonstrated that DAPK 
Kinase Domain 
Ca2+/CaM binding 
Ankyrin repeats 
Cytoskeleton 
 binding 
Death  
Domain N C 
P-loops 
79.8% 
83.3% 
48.5% 
51.9% 
DAPK2/DRP1 
DAPK3/ZIPK 
DRAK2 
DAPK1 
DRAK1 
Leucine-zipper 
40 aa tail 
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interferes with directional persistence during random migration and with cell 
polarization during directed migration and that these effects of DAPK are mainly 
mediated by its suppression of the integrin–Cdc42 signaling axis. Even in tumor cells 
that are resistant to DAPK-induced apoptosis, DAPK can elicit this motility-inhibitory 
effect and functions as a determining factor in tumor cell invasion (Kuo et al., 2006).  
  
3.1.1.2 DAPK signal transduction 
It has been shown that TGFβ activates DAPK promoter through the action of the 
transcription factors Smad2, Smad3, and Smad4 (Jang et al., 2001). Futhuremore, 
Martoriati et al. (2005) demonstrates that DAPK is a target of the transcription factor 
p53. DAPK is up-regulated by hyperproliferative signals, and operates upstream of 
p19ARF and p53 to induce apoptosis. Whereas the inactivation or loss of DAPK 
significantly reduces the p53 responses to c-Myc or E2F-1, it does not completely 
eliminate them, indicating that DAPK is not an exclusive player upstream of 
p19ARF/p53 (Raveh et al., 2001). Recent studies showed several mechanisms 
influencing DAPK activity. These include; the phosphorylation by RSK at Ser289, 
which triggers a suppression of DAPK proapoptotic function (Anjum et al., 2005), the 
autophosphorylation site, which was mapped to Ser308 within the CaM-regulatory 
domain (Shohat et al., 2002), ERK-phosphorylation of DAPK at Ser735, which 
stimulates DAPK-mediated apoptosis (Chen et al., 2005), phosphorylation of DAPK 
by SRC at Tyr491/492, which induces DAPK intra-/intermolecular interaction and 
inactivation, and 5) dephosphorylation by LAR at pTyr491/492 to stimulate the 
catalytic, proapoptotic, and antiadhesion/antimigration activities of DAPK (Wang et 
al., 2007). Furthermore, cathepsin B can directly interact with DAPK, forming a stable 
immune complex mediated by TNFR-1 induction of the changing of DAPK 
localization (Lin et al., 2007). It has been also found that inhibition of HSP90 results 
in degradation of active dephosphorylated DAPK via the ubiquitin proteasome 
pathway. Also DAPK can form heterocomplexes composed of HSP90 and CHIP or 
DIP1/Mib1, indicating that the heightened surveillance and modulation of DAPK 
activities is critical to accurate regulation of apoptosis and cellular homeostasis 
(Zhang et al., 2007). Several substrates of DAPK have been identified shown in table 
1. 
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Substrate Mechanism of action Reference 
myosin II regulatory light 
chain (MLC) 
Mediation of membrane 
blebbing 
Jin et al., 2001 
Syntaxin Syntaxin regulation in 
response to intracellular 
[Ca2+] and synaptic 
activity 
Tian et al., 2003 
p19ARF Linkage of certain 
oncogenes to the 
p19ARF/p53-mediated 
apoptotic checkpoint 
Raveh et al., 2001 
ZIPK Regulation of ZIPK 
intracellular localization 
and association with 
changes in cell motility 
and cell death 
Shani el al., 2004 
Mammalian 40S ribosomal 
protein S6 
Reduction of protein 
synthesis 
Schumacher et al., 2006 
Protein kinase D (PKD) Activation of JNK 
signalling under oxidative 
stress 
Eisenberg-Lerner et al., 
2007 
 
Table 1: Substrates of DAPK 
 
3.1.1.3 DAPK in cancer 
A role for DAPK in the activation of a p19ARF/p53 cell cycle checkpoint has been 
established (Raveh et al. 2001), thus providing a mechanism whereby loss might 
lead to inactivation of this critical apoptotic pathway in tumorigenesis. Indeed, several 
studies have suggested that loss of DAPK expression or methylation of its associated 
CpG islands (CGI) may be characteristics of highly invasive or metastatic tumours 
(Simpson et al., 2002). More than 100 reports from different laboratories were 
published on DAPK gene methylation in various human tumors. The absence of 
DAPK expression in highly metastatic variants of mouse lung cancer cell lines, in 
contrast to its presence in the low metastatic variants of those same cell lines, led to 
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the study of the role of DAPK expression in lung tumor growth and metastasis (Inbal 
et al., 1997). Additional analysis of primary tumor samples from patients with colon 
cancer revealed that the DAPK gene was methylated in 26% of these tumors (Raveh 
et al., 2001). In an in vivo model of experimental metastasis, reintroduction of DAPK 
by stable transfection in the highly metastatic clones that lost DAPK expression, 
attenuated the metastatic capacities of these cells. A recent study reported that 
DAPK expression in colorectal carcinoma was associated with high apoptotic rate. 
On the other hand this study showed that the DAPK expressing tumor-associated 
macrophages were TUNEL-negative, suggesting a dual function of DAPK 
(Schneider-Stock et al., 2006). 
 
3.1.2 MAPKs 
Cells recognize and respond to extracellular stimuli by engaging specific intracellular 
programs, such as the signalling cascade that leads to activation of the mitogen-
activated protein kinases (MAPKs). All eukaryotic cells possess multiple MAPK 
pathways, which co-ordinately regulate diverse cellular activities running the gamut 
from gene expression, mitosis, and metabolism to motility, survival and apoptosis, 
and differentiation. To date, five distinct groups of MAPKs have been characterized in 
mammals: extracellular signal-regulated kinases (ERKs) 1 and 2 (ERK1/2), c-Jun 
amino-terminal kinases (JNKs) 1, 2, and 3, p38 isoforms α, β, γ, and δ, ERKs 3 and 
4, and ERK5 (Chen et al., 2001 and Kyriakis et al., 2001). Since Saccharomyces 
cerevisiae possesses six different MAPKs, the relative complexity of the human 
genome suggests that there are probably several additional vertebrate MAPK 
subfamilies (Madhani et al., 1998). The most extensively studied groups of vertebrate 
MAPKs to date are the ERK1/2, JNKs, and p38 kinases. MAPKs can be activated by 
a wide variety of different stimuli, but in general, ERK1 and ERK2 are preferentially 
activated in response to growth factors and phorbol esters, while the JNK and p38 
kinases are more responsive to stress stimuli ranging from osmotic shock and 
ionizing radiation to cytokine stimulation (Pearson et al., 2001) 
 
3.1.2.1 P38 
The most well-known role of the p38 family is as a transducer of responses to 
environmental stress such as hyperosmolarity, UV irradiation, heat shock, and 
inhibition of protein synthesis, as well as to receptor occupancy by pro-inflammatory 
Introduction 
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molecules such as endotoxin, TNFα, and IL-1 (Raingeaud et al., 1995; Derijard et al., 
1994; Han et al., 1994). p38 signaling has been implicated in responses ranging from 
apoptosis, cell survival (protection from apoptosis), induction of cytokine genes, 
differentiation, and activation of effector functions (Zarubin et al., 2005). The best-
characterized mechanism for activating p38 is dual phosphorylation of a Thr-Gly-Tyr 
motif by upstream MAPK kinases (MAPKK). A major question is how these 
ubiquitous kinases carry out specific biological effects while seemingly being 
activated by a single mechanism. p38 substrates are numerous and continue to be 
identified; which subsets are phosphorylated in response to different stimuli, how they 
are activated, and their roles in cell-specific p38 signaling remain to be sorted out 
(Schaeffer et al., 2000). 
p38 was shown to be present in both the nucleus and cytoplasm of quiescent cells, 
but upon cell stimulation, the cellular localization of p38 is not well understood. Some 
evidence suggests that, following activation, p38 translocates from the cytoplasm to 
the nucleus (Raingeaud et al., 1995), but other data indicate that activated p38 is 
also present in the cytoplasm of stimulated cells (Ben-Levy et al., 1998). 
 
3.1.2.2 P38 in cancer 
p38 has recently gained attention as a tumor suppressor. A comparison of 20 human 
hepatocellular carcinomas with adjacent nonneoplastic tissue showed that p38 was 
significantly less active in tumors; additionally, the larger the tumor, the less p38 
activity was detected (Iyoda et al., 2003). Other studies showed that oncogenic Ras 
cannot induce transformation unless p38 is silenced (Pruitt et al., 2002; Ellinger-
Ziegelbauer et al., 1999). Overall, these studies indicate that sustained p38 activity is 
consistent with dormancy behavior and inconsistent with proliferation and growth of 
primary tumors in vivo. Thus it appears that p38 activation ought to suppress 
oncogenesis. Indeed, when p38 activity was forced in rhabdomyosarcoma cells, it 
induced terminal differentiation (Puri et al., 2000). Similarly, deletion of a p38- 
inhibitory phosphatase blocked Hras1- and erbB2-induced carcinogenesis in vivo, 
whereas inhibition of p38 promoted tumor formation (Bulavin et al., 2004). Imposed 
p38 activation in HeLa cells specifically suppressed their tumor-forming ability in vivo 
(Timofeev et al., 2005). Other studies have evaluated p38 activity in the response to 
chemotherapy. The results indicate that diverse chemotherapeutic agents stimulate 
apoptosis in a p38-dependent manner. For example, microtubule-perturbing drugs 
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such as vinblastine, vincristine and taxol induce tumor cell apoptosis that is inhibited 
by treatment with SB203580 (Deacon et al., 2003). In these cells, the basal level of 
apoptosis is 2%, but can be raised to 54% by activating p38 (Deacon et al., 2003). 
Cisplatinin, a DNA damaging agent, also induced p38-dependent apoptosis in 
several cells lines (Losa et al., 2003). Thus, p38 appears to promote tumor cell 
apoptosis, at least in some cases. However, this should not be construed as a 
universal relationship, since p38 activity can also block apoptosis. For example, the 
anthrax lethal factor promotes macrophage apoptosis by inhibiting p38 activity (Park 
et al., 2002). Furthermore, the p38 MAPK inhibitor SB239063 significantly reduced 
TNFα production from LPS-stimulated human lung macrophages (Smith et al., 2006). 
 
3.2 Colorectal carcinoma 
Colorectal cancer, also called colon cancer or bowel cancer, includes cancerous 
growths in the colon, rectum and appendix. According to the World Health 
organization (WHO), it is the third most common form of cancer and the second 
leading cause of cancer-related death in the Western world. Colorectal cancer 
causes 655,000 deaths worldwide per year. It is now generally accepted that 
colorectal cancer develops by genetic alterations. Analysis of the molecular 
mechanism makes it possible to develop a more targeted approach to prevention and 
treatment of this cancer. There are two major pathways in colorectal carcinogenesis. 
One is the chromosomal instability pathway (adenoma-carcinoma sequence), which 
is characterized by allelic losses, and the other is a pathway involving microsatellite 
instability (MSI), described below. 
 
3.2.1 Risk factors and causes 
Most cases of colorectal cancer are due to sporadic factors, namely older age, 
ureterocolic anastomosis, diet (rich in meat and fat, and poor in fibre, folate, and 
calcium), obesity, diabetes mellitus, smoking, previous irradiation, and high alcohol 
intake. Another category of colorectal cancer risk factor is inflammatory bowel 
disease, including ulcerative colitis and crohn's colitis. Finally, Hereditary factors are 
also colorectal cancer risk factors. Roughly 5–10% of all colorectal cancers develop 
in the setting of defined hereditary cancer syndromes. The two main forms are 
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hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous 
polyposis (FAP). 
 
3.2.1 Pathogenesis 
The majority of colorectal cancers develop from adenomas. The progression from an 
adenoma to a cancer passes through a series of defined histological stages referred 
to as the adenoma-carcinoma sequence (Fig. 3) (Vogelstein et al., 1988). The 
colorectal tumour initiation requires several different somatic changes before a cell 
can develop into a carcinoma (Kinzler et al., 1996). 
 
3.2.1.1 Chromosomal instability pathway 
Fearon and Vogelstein et al. (1990) proposed a multistep model of colorectal 
carcinogenesis, in which mutations in the adenomatous polyposis coli (APC) gene 
occur early during the development of polyps, K-ras mutations arise during the 
adenomatous stage, and mutations of p53 and deletions on chromosome 18q occur 
concurrently with the transition to malignancy. This pathway is characterized by allelic 
losses on chromosome 5q (APC), 7p (p53), and 18q (DCC/SMAD4), and is therefore 
called the chromosomal instability (CIN) pathway. One of the cornerstones of the CIN 
pathway is the model represented by FAP, in which multiple small adenomas form as 
a result of initiation of tumorigenesis, namely, two hits in the APC gene, followed by 
mutations of K-ras, and subsequently mutations of p53 and deletion on chromosome 
18q. Furthermore, it has been shown that DAPK promotor methylation is an early 
event in colorectal carcinogenesis (Mittag et al., 2005). It has been suggested that, 
the same mechanism is also applicable to sporadic colorectal carcinogenesis.  
 
 
FIG. 3. Main events in the adenoma-carcinoma sequence (Vogelstein et al., 
1988; Boland et al., 1995) 
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3.2.1.2 Microsatellite instability pathway 
Microsatellite instability (MSI) is characterized by expansions or contractions in the 
number of tandem repeats of simple DNA sequences (microsatellites). MSI has been 
identified in colorectal cancer associated with HNPCC syndrome (Ionov et al., 1993, 
Thibodeau et al., 1993, and Aaltonen et al., 1993), and DNA mismatch repair (MMR) 
enzymes, including hMSH2, hMLH1, hPMS1, hPMS2, and hMSH6, have since been 
shown to be responsible for MSI (Fishel et al., 1993, Bronner et al., 1994, Nicolaides 
et al., 1994, Nicolaides et al., 1995, and Papdopoulos et al.,1995). Moreover, 
mutations in microsatellites of target genes such as the transforming growth factor-β 
(TGF-b) gene have also been identified in MSI positive tumors (Markowitz et al., 
1995).  
 
3.3 Tumor-associated macrophages (TAMs) 
It is widely accepted that tumour-associated macrophages (TAMs) represent a major 
and important component of the leukocyte infiltrates of many tumours and metastatic 
deposits (Mantovani et al., 1986 and Volodko et al., 1998). It has been established 
that TAMs have pleiotropic functions, which can influence tumour growth, both in 
terms of progression and regression. This differential effect of TAMs is believed to be 
regulated by modulation of the host immune system (Mills et al., 1992 and Elgert et 
al., 1998). Tumour growth reduction by TAMs can be mediated by non-specific anti-
tumour cytotoxic mechanisms or induction of specific cell lytic effects (Grabbe et al., 
1994 and Blachere et al., 1997). On the other hand, there is convincing data for 
TAMs demonstrating tumour cell growth-promoting effects through release of various 
cytokines and prostanoids (Sunderkotter et al., 1994 and Parajuli et al., 1996). Also, 
macrophages have been shown to suppress many T cell (Alleva et al., 1994 and Aoe 
et al., 199) and NK cell (Aso et al., 1992) anti-tumour responses. What determines 
the outcome of these competing interactions and subsequent defined macrophage 
functions during tumour growth, as yet, is still poorly defined. An understanding of the 
complex regulatory mechanisms, therefore, that control macrophage functions during 
tumour growth is critical to planning therapeutic approaches to achieving 
improvement of patient well being and control of the malignant process. 
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3.3.1 TAM repression of Tumor Growth  
Macrophages, particularly when activated, can be cytostatic or cytotoxic for tumour 
cell growth (Fidler et al., 1988; Owen et al., 1998 and Killion et al., 1998). In 1959, 
Biozzie observed that Bacille Calmette-Guérin (BCG)- a non-specific activator of the 
‘reticulo-endothelial system-when inoculated into mice, was able to decrease the 
growth of certain tumours. Since these early observations, many reports have 
demonstrated that non-specific stimulants, known to activate macrophages, may 
inhibit tumour growth in animals when administered at an appropriate time interval in 
relation to inoculation of tumour cells. Also, it was observed that when grafts of 
tumour cells, transfected with the genes encoding for interferon (IFN)-g, IL-2 and 
TNFα, were rejected, activated macrophages were present in the tissues at the sites 
of inoculation. Furthermore, specific antibodies that blocked the recruitment of 
macrophages inhibited the rejection response (Colombo et al., 1992).  
Macrophage-derived cytokines have been shown to be cytotoxic against a range of 
tumour cells (Bonta et al., 1991 and Ben-Efraim et al., 1994). IL-1 has been 
demonstrated to be cytotoxic and cytostatic for tumour cells (Ichinose et al., 1988). 
Also, it has been demonstrated that IL-1 can act synergistically or additively with 
TNFα in killing tumour cells. TNFα is capable of causing haemorrhagic necrosis of 
certain transplantable tumors in vivo (Carswell et al., 1975), and capable of direct 
tumour cytotoxicity in vitro. TNFα is produced primarily by monocytes and 
macrophages. This has led to the postulate that TNFα is involved in the delivery of 
the lethal hit of some tumours (Klostergaard et al., 1987 and DeMarco et al., 1992). A 
crucial role for TNFα in macrophage-mediated anti-tumour cell cytotoxicity has been 
demonstrated in two experimental studies. The first series of investigations 
demonstrated that UV-induced tumour clones, selected for resistance to 
macrophages, were resistant to TNFα (Urban et al., 1988). The second series of 
experiments showed that anti-TNFα antibodies inhibited macrophage cytotoxicity. 
More definitive experiments should now be possible with the advent of knockout mice 
in which the genes for TNFα and its receptors are deleted (Erickson et al., 1994). 
Numerous cells of immunosurveillance are known to microscopically infiltrate in 
cancers. These infiltrating immunosurveillance cells, including mast cell (MCs) and 
tumor associated macrophagel (TAMs), have been found to reflect a tumor-related 
immune response (Ghiara et al., 1985, Hensweson et al., 1981, Alleva et al., 1993, 
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and Tani et al., 2001). Although TAMs have the potential to mediate tumor 
cytotoxicity and to stimulate antitumor lymphocytes[3], it is still unclear whether TAMs 
can predict tumor prognosis. MC and TAM count were found to have a direct 
relationship with clinical outcome in patients with colorectal cancer. In this study, 
authors showed that, MCs and TAMs may play an important role in the enhancement 
of host immunity against cancer cells and that an increase in MCs and TAMs may 
improve the postoperative prognosis of patients with colorectal cancer. It is beneficial 
for estimating biological character of colorectal carcinoma to combine MC and TAM 
counts, thus enhancing immunosurveillance. Finally, in advanced gastric carcinoma, 
the number of TAMs in close proximity to tumor cells in tumor cell nests correlates 
positively with tumor cell apoptosis, suggesting that TAMs or TAM effector cells are 
actively involved in tumor cell destruction. Notably, tumors that have large numbers of 
"nest TAM" are associated with a significant increase in 10-year disease-free survival 
(Ohno et al., 2003). 
 
3.3.2 TAM induction of Tumour Growth  
TAMs have been shown to play a key role in tumour growth and dissemination and in 
some of the systematic manifestations of neoplasia. Mononuclear phagocytes can 
produce a range of growth factors, including platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF) and transforming growth factor (TGF)-b, as well as 
cytokines such as TNFα and IL-1, that have been shown to enhance metastatic 
spread in several animal tumour models (Opdenakker et al., 1992; Leek et al., 1996; 
Salvesen et al., 1999 and Takanami et al., 1999). It is not surprising, therefore, that 
TAMs can promote the growth of tumour cells, an activity best observed in vitro at 
low effector to target cell ratios or with tumour cells in suboptimal culture conditions 
(Auger et al., 1992 and Mantovani et al., 1986).  
There are several evidence demonstrating that, unlike macrophages from healthy 
tissues, which are capable of presenting tumor-associated antigens, lysing tumor 
cells, and stimulating the antitumor functions of T cells and NK cells, TAMs in the 
tumor microenvironment lack these activities, leaving the host without the ability to 
mount an effective antitumor immune response. A number of studies have shown that 
tumor-derived molecules, like cytokines, growth factors, chemotactic molecules, and 
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proteases, influence TAM functions (Elgert et al., 1998, Sunderkotter et al., 1991, and 
Ben-Baruch et al., 2005). For example, tumor cells secrete IL-4, IL-6, IL-10, MDF, 
TGF-ß1, and PGE2, which inhibit the cytotoxic activity of TAMs (Elgert et al., 1998 
and Ben-Baruch et al., 2005). Moreover, TGF-ß1, IL-10, and PGE2 may suppress the 
expression of MHC class II molecules by macrophages in the tumor 
microenvironment as well as distant sites like the spleen and peritoneum. This effect 
may limit the ability of TAMs to present tumor-associated antigens to T cells 
effectively in these areas (Elgert et al., 1998). Thus, tumors undergo immunoediting 
to down-regulate macrophage functions that are potentially dangerous to the tumor 
even in circumstances where recognizable tumor antigens are presented. It should 
be noted that the tumoricidal activity of TAMs may vary markedly in different tumor 
microenvironments.  
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4. Thesis aims and proposal 
 
 
Recently, Schneider-Stock et al. (2006) demonstrated that a high DAPK1 expression 
in colorectal tumors and surrounding macrophages was associated with a high 
apoptotic rate in in tumor cells but not in TAMs, suggesting a new function of DAPK1 
in apoptosis induction during the cross talk between colorectal tumor cells and TAMs. 
However, the role of DAPK1 regulation in macrophages-induced tumor cell death and 
macrophage survival is still unknown. 
The objective of the thesis was to establish an in vitro model, using conditioned 
supernatants of differentiated/activated macrophages and HCT116 colorectal tumor 
cells, which recapitulates the above in vivo observed findings and reflects the in vivo 
tumor settings (Fig. 4). 
 
• Supernatant study
Principle :
Collect supernatants of the differentiated and activated macrophages (U937)
Collect supernatants of the HCT116p53+/+ and HCT116p53-/-
HCT116p53+/+ or HCT116p53-/-
Conditioned
supernatants
U937 (differentiated or activated macrophages)
 
 
 
FIG. 4. Thesis Proposal: Effects of HCT116- and macrophages-conditioned 
supernatants on DAPK expression and function. 
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The aims of the thesis were to study DAPK function and regulation in two directions: 
 
1- Macrophage                Tumor cell       
                  
• To understand the mechanisms underlying the apoptosis induction in the 
tumor cells and whether it is mediated by the macrophages-supernatants. 
• To investigate which mediator(s), released from macrophages, is/are involved 
in DAPK induction. 
• To study if the apoptosis induction is DAPK1-dependent. 
• To examine the upstream signalling pathway, which contributes to the 
DAPK1/apoptosis induction. 
• To verify the physiological relevance of DAPK regulation in the in vivo settings. 
 
2- Tumor cell                 Macrophage  
         
• To demonstrate whether the apoptosis resistance in macrophages is mediated 
by DAPK1. 
• To study the effects of tumor cells-supernatants on the differentiated/activated 
macrophages. 
• To investigate upstream/downstream mechanisms in DAPK-triggered 
macrophage survival. 
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5.1 Materials 
5.1.1 Laboratory equipment 
0.45 µm sterile filters    BD Falcon, France 
–20ºC Freezer      Siemens AG, Germany 
4ºC Fridge       Siemens AG, Germany 
5 ml FACS tubes      BD Biosciences, Belgium 
–80ºC Freezer      Heraeus, Hanau, Germany 
Automatic pipettes      Gilson, Middleton, WI, USA 
AxioCam MRc5 camera     Carl Zeiss GmbH, Germany 
Blotting chamber      Bio-rad, Munich, Germany 
Coulter Counter ZII     Coulter Immunotech, Germany 
Centrifuges       Eppendorf, Germany 
CO2 Incubators      Heraeus, Rodenbach, Germany 
Digital Precision Scale     KERN & Sohn GmbH, Germany 
Fluorescence-activated cell sorter (FACS)  BD Biosciences, Belgium 
Gel electrophoresis systems    Bio-rad, Munich, Germany 
Heating block      Biometra, Germany 
Hyperfilm       Amersham Biosciences, Germany 
Kinetic microplate reader     Molecular Devices, Sunnyvale, USA 
Laminar flow hoods     Heraeus, Hanau, Germany 
Liquid nitrogen tank     MVE, New Prague, MN, USA 
Light Cycler       Roche Diagnostics GmbH, Germany 
Microscopes      Carl Zeiss GmbH, Germany 
pH-meter       WTW, Weilheim, Germany 
Photometer       Eppendorf, Germany 
PTC-200 Peltier Thermal Cycler   MJ Research, Germany 
Rocking Platforms      Biometra GmbH, Göttingen, Germany 
Rotary microtome      Leica Microsystems GmbH, Germany 
Semi-Dry Electrophoretic Transfer Cell   Bio-rad, Munich, Germany 
Sterile cell scrapers     TPP, Switzerland 
Sterile tissue culture plastic flasks, plates,  NUNC, Denmark 
dishes   
Sterile tissue culture plastic tubes, pipets  Eppendorf, Germany 
Vortex       IKA Works, Wilmington, NC, USA 
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Water bath       GFL, Burgwedel, Germany 
X-ray film developing machine    AGFA, Germany 
 
5.1.2 Chemical reagents and other research solutions 
2-Mercaptoethanol      Merck, Darmstadt, Germany 
3,3′,5,5′-Tetramethylbenzidine tablets (TMB)  Sigma-Aldrich GmbH, Germany 
3-(4,5-dimethylthiazol-2-yl)-    Sigma-Aldrich GmbH, Germany 
2,5-diphenyltetrazolium bromide (MTT) 
30% Acrylamide/Bis Solution    Roth, Karlsruhe, Germany 
4',6-diamino-2-phenylindole (DAPI)   Molecular Probes, USA 
D,1-Dithiothreitol (DTT)     Sigma-Aldrich GmbH, Germany 
Acetic acid 96%      Sigma-Aldrich GmbH, Germany 
Ammonium Persulfate     Sigma-Aldrich GmbH, Germany 
Aprotinin       Roche Diagnostics GmbH, Germany 
32
-ATP       Amersham Biosciences, Germany 
Biotinylated Protein Ladder   Cell Signaling Inc., Germany 
Bovine serumalbumin (BSA)    Sigma-Aldrich GmbH, Germany 
DNA Molecular weight Marker VIII   Roche Diagnostics GmbH, Germany 
Dimethylsulfoxide (DMSO)    Sigma-Aldrich GmbH, Germany 
EDTA       Sigma-Aldrich GmbH, Germany 
Ethanol       Merck, Darmstadt, Germany 
Glycerol       Merck, Darmstadt, Germany 
Glycine for electrophoresis   Merck, Darmstadt, Germany 
Griess Reagent     Sigma-Aldrich GmbH, Germany 
HEPES       NeoLab GmbH, Germany 
Isopropanol       Merck, Darmstadt, Germany 
Leupeptin A       Roche Diagnostics GmbH, Germany 
LPS        Sigma-Aldrich GmbH, Germany 
Magnesium Chloride     Merck, Darmstadt, Germany 
Methanol       Merck, Darmstadt, Germany 
Nonidet P-40      Roche Diagnostics GmbH, Germany 
Phenylmethylsulfonyl fluoride (PMSF)   Sigma-Aldrich GmbH, Germany 
PMA        Sigma-Aldrich GmbH, Germany 
Polyethylenglycol 6000 P.E.G   FERAK LABORAT GmbH, Germany 
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Ponceau S       Sigma-Aldrich GmbH, Germany 
Protease inhibitor cocktail Set    Calbiochem, Germany    
Skim milk powder (blotting grade)   Sigma-Aldrich GmbH, Germany 
Sodium Chloride      Merck, Darmstadt, Germany 
Sodium Citrate      Sigma-Aldrich GmbH, Germany 
Sodium Hydroxide      Sigma-Aldrich GmbH, Germany 
Sodium Vanadate      Sigma-Aldrich GmbH, Germany 
Sodiumdodecylsulfat (SDS)    Biorad, Munich, Germany 
Sulphuric Acid      Merck, Darmstadt, Germany 
Tetramethylethylendiamine (TEMED) ICN  Biomedicals Inc, Aurora, USA 
Tris base       Sigma-Aldrich GmbH, Germany 
Triton-X100       Sigma-Aldrich GmbH, Germany 
Trizol        Invitrogen Corporation, Germany 
Human fibronectin      Sigma-Aldrich GmbH, Germany 
Tween 20       Merck, Darmstadt, Germany 
 
5.1.3 Cell lines 
Five human Colorectal cancer cell lines were used and one human pre-monocytic 
cell line (U937). All cell lines were purchased from either DSMZ (DSMZ 
Braunschweig, Germany) or ATCC (ATCC, Manassas, VA). 
 
 Cell line   Histological origin  Medium Source 
HCT116 p53 +/+       colorectal carcinoma   RPMI  ATCC 
HCT116 p53 -/-       colorectal carcinoma   DMEM ATCC 
HT29         colorectal adenocarcinoma  RPMI  DSMZ 
CaCo         colorectal adenocarcinoma  RPMI  ATCC 
SW480        colorectal adenocarcinoma  RPMI  DSMZ 
U937         histiocytic lymphoma   RPMI  DSMZ 
 
5.1.4 Media and supplements 
Trypsin-EDTA      PAN, Germany 
RPMI 1640      PAN, Germany 
Dulbecco´s Modified Eagle Medium (D-MEM)  PAN, Germany 
Fetal Bovine Serum (FBS)    PAN, Germany 
Fetal Calf Serum      PAN, Germany 
Materials and Methods 
 - 25 -
Penicillin-streptomycin mixture    PAA, Germany 
 
5.1.5 Kits and other research products 
Avidin-biotinylated Horseradish 
Immobilon Western Chemiluminescence  Pierce, Rockford, USA 
Bio-Rad Dc Protein     Biorad, Munich, Germany 
DeadEnd™ Fluorometric TUNEL System  Promega, Madison, WS, USA 
ECL® Western Blotting Detection System  Amersham Biosciences, Germany 
Enhanced Chemiluminescence System  Amersham Biosciences, UK 
CpGenomeTM DNA Modification Kit  Chemicon International, USA 
Human TNFα Immunoassay Kit    R&D Systems, Minneapolis, MN, USA 
Human IFNγ Immunoassay Kit    ImmunoTools, Germany 
Immunoprecipitation Kit     Amersham Biosciences, Germany 
Restore™ Western Blot Stripping Buffer  Pierce, Rockford, IL, USA 
Annexin-V-FLOUS     Roche Diagnostics GmbH, Germany 
Omnia Plate IP Kit (p38 MAPK)    BioSource, USA 
Caspase-Glo™ 3/7 Assay kit   Promega, Madison, WS, USA 
 
5.1.6 Antibodies 
Anti-DAPK monoclonal     BD Biosciences, Belgium 
Anti–p83       Cell Signaling Inc., Germany 
Anti–phospho-p38      Cell Signaling Inc., Germany 
Santa Cruz Biotechnology, CA, USA 
Anti-ERK1/2       Cell Signaling Inc., Germany 
Anti-phospho-ERK1/2     Cell Signaling Inc., Germany 
Anti-SAPK/JNK      Cell Signaling Inc., Germany 
Anti–phospho-SAPK/JNK    Cell Signaling Inc., Germany 
Anti–phospho-p38      Cell Signaling Inc., Germany 
Anti–RSK1       Cell Signaling Inc., Germany 
Anti-p53       Oncogene, San Diego, CA 
Anti–caspase 3      Cell Signaling Inc., Germany 
Anti-ß-actin monoclonal     Sigma-Aldrich GmbH, Germany 
Goat anti-mouse     Sigma-Aldrich GmbH, Germany 
Goat anti–rabbit     Sigma-Aldrich GmbH, Germany 
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Goat anti–rabbit     Cell Signaling Inc., Germany 
 
5.1.7 Software 
Adobe Acrobat 5.0      Adobe Systems Inc., USA 
Adobe Acrobat Distiller 5.0    Adobe Systems Inc., USA 
Adobe Photoshop 5.0     Adobe Systems Inc., USA 
AxioVision 4.4      Carl Zeiss GmbH, Germany 
SOFTmax 2.32      Molecular Devices Corp., USA 
Gene Tools      Syngene, Cambridge, UK 
Windows XP Professional    Microsoft Corporation, USA 
 
5.1.8 Database 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
 
5.1.9 Buffers 
PBS Wash Buffer, 1X 
140 mM  NaCl 
2.7 mM  KCl 
10 mM  Na2HPO4 
1.8 mM  KH2PO4 
High purity dH2O, pH 7.4 
 
PBS-T 
1X PBS 
0.1%   Tween-20 
 
DAP Kinase Buffer, 1X 
60 mM  HEPES-NaOH, pH 7.5 
3 mM   MgCl2 
3 mM   MnCl2 
0.003 M  sodium orthovanadate 
1.2 mM  DTT 
2.5 µg/µl  PEG 
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Protein Lysis Buffer 
4 M   Urea 
0.5%   SDS 
62.5 mM  Tris, pH 6.8 
 
RIPA Lysis Buffer, 1X 
50 mM  Tris-HCl, pH 7.4 
150 mM  NaCl 
1% Nonidet  P-40 
0.5%   Sosium deoxycolate (DOC) 
1 mM  PMSF 
1 µg/ml  Aprotinin 
1 µg/ml  Leupeptin 
Protease and phosphatase inhibitors were added freshly before cell lysis. 
 
Laemmli Buffer, 2X 
1.25 M  Tris-HCl, pH 6.8 
1 M   DTT 
0.1%   Bromophenol Blue 
20%   Glycerol 
4%   SDS 
 
IP Wash Buffer 
50 mM  Tris, pH 8.0 
 
Loading Buffer, 5X 
4 M   Urea 
10%   SDS 
62.5   mM Tris 
20%   DTT 
 
Towbin Transfer Buffer, 1X 
25 mM  Tris-HCl, pH 8.3 
192 mM  Glycine 
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20%   Methanol 
     High purity dH2O 
 
Tris Buffered Saline (TBS) Buffer, 10X 
1M   Tris-HCl, pH 7.4 
1.5M  NaCl 
 
TBS-T Buffer 
1X   TBS 
0.1%   Tween-20 
 
SDS Electrophoresis Buffer, 10X 
0.25 M  Tris 
1.92 M  Glycine 
1%   SDS 
High purity dH2O, pH 8.3 to 1000 ml 
 
OLD-T Puffer 
40 mM  Tris/HCl, pH7.5  
150 mM  NaCl  
25 mM  EDTA, pH7,5 
 
Separating gel Buffer 
1.875 M  Tris 
1%   SDS 
High purity dH2O, pH 8.8 to 200 ml 
 
Stacking gel Buffer 
1.875 M  Tris 
0.5%   SDS 
High purity dH2O, pH 6.8 to 200 ml 
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Solutions for Casting One 10% Separating and One Stacking Gel 
Separating gel, 10%  Stacking gel 
H2O      4.67 ml       6.33 ml 
30% Acrylamide/Bis Solution  3.33 ml       1.65 ml 
Separating gel Buffer   2 ml            - 
Stacking gel Buffer       -        2 ml 
10% Ammonium Persulfate 0.075 ml       0.075 ml 
TEMED     0.008 ml       0.008 ml 
 
Milk Blocking Solution 
5% w/v nonfat dry milk dissolved in TBS-T buffer 
 
Ponceau S Staining Solution 
0.5 g of Ponceau S was dissolved in 1 ml of glacial acetic acid and the volume 
was adjusted to 100 ml with H2O. 
 
TMB Substrate Solution 
One tablet of the HRP substrate TMB was dissolved in 10 ml of phosphate 
citrate buffer with 2 µl of 30% H2O2. 
 
Coating buffer 
0.1 M   Sodium carbonate 
8.4 g   NaHCO3 
3.56 g  Na2CO3 
High purity dH2O, pH 9.5 to 1000 ml 
 
Assay Diluent 
1X   PBS 
10%   FCS, pH 7.0 
 
Phosphate-Citrate buffer 
0.2 M   Na2HPO4*H2O 
0.1 M   C6H8O7*H2O 
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ELISA stop solution 
1 M   H3PO4 
 
5.2 Methods 
5.2.1 Cell biological methods 
5.2.1.1 Cell culture techniques 
The cells were cultivated under aseptic conditions in 75-cm2 tissue culture flasks. All 
tissue culture flasks have caps with filters which allow gaseous exchange, allowing 
maintenance of correct pH (which is monitored by the colour of the phenol red 
present in the medium) and the right percentage of CO2 (5%). The optimal 
atmosphere conditions are allowed by CO2 incubator, which automatically control 
temperature and pCO2; it operates with a try of water on the base in an attempt to 
maintain more than 98% relative humidity. Temperature of the incubator was set at 
37°C and regularly controlled. The five human color ectal cancer cells maintained as 
monolayer cultures in RPMI1640 medium, except the HCT116 p53-/- cells in DMEM 
meium, and supplemented with 10% FBS and 1% penicillin-streptomycin mixture. 
Cells of the U937 monocyte/macrophage cell line were also maintained in RPMI 
1640. Growth medium was changed every 2-3 days. The cells were split into the new 
culture flasks when they reached 80-90% confluence. Old medium was removed and 
the cells were washed twice with sterile PBS buffer. Then 1 ml of trypsin-EDTA 
solution was added, the culture flask was incubated at 37°C and observed under the 
microscope until cells detached from the surface of the flask. Then 10 ml of complete 
fresh medium was added to inactivate the activity of trypsin. Medium was discarded 
and the cells were re-suspended in fresh growth medium. 
 
5.2.1.2 Adapting HCT116 p53 -/- to RPMI 1640 medium 
To adapt the HCT116 p53-/- to grow in RPMI 1640 medium, cell were subcultured at 
a 1:2 split ratio into two identical culture vessels with one vessel containing the 
DMEM medium and the other containing a mixture of 50% DMEM and 50% RPMI 
1640. The effects of the new medium formulation on the cells were observed by 
comparing the growth in the cultures with the medium mixture with the culture 
containing only the DMEM medium formulation. When the cells in the mixed culture 
became confluent, the process was repeated by again splitting the mixed culture at a 
Materials and Methods 
 - 31 -
1:2 ratio into two identical vessels. The vessel then was containing 50% original 
medium and 50% new medium while the second culture had 25% original medium 
and 75% new medium. Once second culture became confluent the cells were 
subcultured into 100% new medium of RPMI1640. 
 
5.2.1.3 Cell stimulation with different factors 
Monocytes monocytic cell line U937 cells (DSMZ Braunschweig, Germany) were 
maintained in RPMI with 10% fetal bovine serum and 1% penicillin-streptomycin 
mixture in a humidified 5% CO2 atmosphere at 37°C.   
For PMA/LPS induction experiment, U937 (4 × 106/ml) cells were first differentiated 
into macrophages in the presence of 16 nM phorbol 12-myristate 13-acetate (PMA) 
for 72 hours and then washed 3 times with PBS and recovered for 24 hours. 
Undifferentiated floating Cells and dead cells were washed away with three rinses of 
warm PBS. The attached macrophages were then stimulated with 1-10 ng/ml 
lipopolysaccharide (LPS) for 1-24 hours in the growth media. The culture 
supernatants were later centrifuged at 12000 rpm and collected as conditioned 
medium.  
 
 
FIG 5. Morphology of U937; monocytes and differentiated macrophages after 
incubation with 16 nM PMA for 72h.  
16 nM PMA pre-incubation (72h) Adherent cells + LPS (1, 5, 10 
ng/ml) 
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Human Monocyte isolation, differentiation and culture. PBMCs were isolated 
from freshly drawn human blood using Ficoll-Plaque technique and Density gradient 
Centrifugation. The monocytes were separated by negative selection with an 
AutoMACS magnetic cell isolation system according to the manufacturer´s 
instructions (Miltenyi). Monocyte purity was evaluated by immunofluorescent staining 
and flow cytometry using a monoclonal antibody for CD14 (BD Pharmingen). 4 x 105 
Cells per ml were cultured in RPMI-1640 medium including FCS and Pen/Strep. 
Monocytes were activated with or without 10 ng/ml LPS for 4 h in 50mm culture 
dishes (Corning). Culture medium supernatants were collected for determination of 
TNFα concentrations (ELISA) and applied to HCT116 p53 +/+ cells for 6h or 24 h.  
 
Colorectal cancer cell lines 
Cells were maintained in RPMI with 10% FBS and 1% penicillin-streptomycin mixture 
in a humidified 5% CO2 atmosphere at 37°C. Cells (1 .2 x 106) were cultured for 6-72 
hours in either normal, or macrophages-conditioned medium, or with cytokines, TNF-
α and IFN-γ (Immunotools, Germany). 
 
5.2.1.4 Storage of cells 
In order to minimize the cellular injury induced by freezing and thawing procedures 
(intracellular ice crystals and osmotic effects), a cryoprotective agent DMSO was 
added. A variable number of cells (between 1-2 x 106) was spin down and 
resuspended in 10% DMSO solution (DMSO diluted in FBS). Afterwards, 1 ml 
aliquots of cell suspension were dispensed into criotubes (1.8 ml). The tubes were 
placed into wells of a brass block pre-cooled at 4°C. The block was then kept at –
80°C for 24 h after which the ampoules of cells wer e transferred to liquid nitrogen for 
long-term storage. For revival of cells a frozen ampoule was thawed rapidly in a 37°C 
water bath, disinfected and the content was put in a cell culture flask with pre-
warmed medium. After 6 hours the medium was discarded and fresh pre-warmed 
medium was added. 
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5.2.2 Biochemical methods 
5.2.2.1 DNA extraction 
It is a liquid-liquid extraction technique in biochemistry and molecular biology for 
purifying DNA contaminated by histones and other proteins. Equal volumes of a 
phenol:chloroform mixture and the aqueous DNA sample are mixed, forming a 
biphasic mixture. The proteins will partition into the organic phase while the DNA (as 
well as other contaminants such as salts, sugars, etc.) remain in the aqueous phase. 
This is usually repeated at least once and often more, depending on the 
requirements of the downstream processes, and then followed by precipitation with 
ethanol. OLD-T-buffer, 10% SDS, and Proteinase K were added to cell pellets. Cell 
pellets were then incubated overnight by 50 °C on t he thermoshaker. On the next day 
phenol was added two times to the tubes and the upper layer was collected by 
centrifugation (7500 rpm, 4 °C). Choloroform/Isoamy alcohol (24:1) was added to the 
tubes and then they were centrifuged (7500 rpm, 4 °C). the supernatants were then 
collected and DNA wasd then precipitated with 3 M Sodium Acetate and 100% 
alcohol.  
 
5.2.2.2 Methylation-specific PCR (MSP) 
The initial step of both bisulfite genomic sequencing and MSP is to perform a bisulfite 
modification of the DNA sample. MSP then involves PCR amplification with specific 
primers designed to distinguish methylated from unmethylated DNA. The 
CpGenome™ Fast DNA Modification Kit contains the reagents for the initial bisulfite 
modification of the DNA required for both methodologies. 
MSP requires an initial bisulfite reaction, using 200 to 500 ng genomic DNA 
(CpGenome DNA Modification Kit, Chemicon), in which all unmethylated cytosines 
are deaminated and converted to uracils, whereas 5-methylcytosines remain 
unaltered. Modified DNA was used as a template for MSP, using primers specific for 
either methylated or modified unmethylated sequences. CpGenome universal 
methylated DNA (QBiogene) was used as a positive control for methylated alleles. 
DNA from normal lymphocytes was used as a negative control for methylated alleles. 
Modified DNA was subjected to MSP using DAPK specific primers for methylated 
sequences (sense 5′-GGATAGTCGGATCGAGTTAACGTC-3′ and antisense 5′-
CCCTCCCAAACGCCGA-3′) and for unmethylated sequences (sense 5′-
GGAGGATAGTTGGATTGAGTTAATGTT-3′ and antisense 5′-
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CAAATCCCTCCCAAACACCAA-3′), which generates polymerase chain reaction 
(PCR) products of 114 and 116 bp, respectively. The total 25 µl of PCR mix 
contained 2 µl of bisulfite-modified DNA, 1x PCR buffer, 3 mM MgCl2, 12.5 pmol of 
each primer, 160 µM dNTPs, and 0.5 U of Hot-Goldstar Taq polymerase 
(Eurogentec, Seraing, Belgium). PCR conditions were as follows: 95°C for 10 
minutes, 35 cycles of 95°C for 1 minute, annealing with 60°C for 1 minute and 72°C 
for 1 minute, followed by a final extension step at 72°C for 10 minutes. Methylated 
standard DNA (Intergen) was used as a positive control for methylation, and placenta 
DNA was used as a negative control.  
 
5.2.2.3 Measuring of RNA concentration 
DNA was quantified by spectrophotometric analysis on the basis of its extinction 
using 1 OD260 = 40 µg/ml and diluted 5:65 with DEPC-H2O. The absorbance was 
checked at 260 and 280 nm for determination of sample concentration and purity. 
The A260/A280 ratio was between 1.7 and 2.1 for pure DNA. All DNA stock solutions 
were stored at -20°C. 
 
5.2.2.4 Visualizing PCR products 
The PCR products (7µl) along with a DNA marker were resolved on 8% 
polyacrylamide gels with silver nitrate staining. Briefly, the silver staining method 
involved; treatment with 3% HNO3 for 2 to 3 min followed by a 5-min rinse in water; 
impregnation of the gel with 0.2% AgNO3 for 20 min and water rinse for 2-3 min; 
developing of the gel with developer (3% Na2CO3 and 0.75 ml of 37% formaldehyde) 
for 2.5 min, followed by a brief rinse in water and 2 min in 10% citric acid stop 
solution; post fixation with 5% glycerol for 20 min. The gels were dried at room 
temprature. 
 
5.2.2.5 RNA extraction 
Total RNA extraction was preformed using Trizol reagent (invitrogen). Cell pellets 
were homogenized and re-suspended in 1ml of Trizol and incubated for 5 minutes at 
room temperature. Chloroform (0.5ml) was added to the suspension, which was 
incubated for 5 minutes at room temperature and centrifuged at 15,000 rpm to 
achieve phase separation (organic phase from aqueous phase). The aqueous phase, 
Materials and Methods 
 - 35 -
containing the RNA, was transferred to a new tube, and RNA was recovered by 
precipitation with isopropyl alcohol. The precipitated RNA was dissolved in 50-200 µl 
DEPC-H2O.  
 
5.2.2.6 Measuring of RNA concentration 
RNA was quantified by spectrophotometric analysis on the basis of its extinction 
using 1 OD260 = 40 µg/ml and diluted 1:70 with DEPC-H2O. The absorbance was 
checked at 260 and 280 nm for determination of sample concentration and purity. 
The A260/A280 ratio was between 1.7 and 2.1 for pure RNA. All RNA stock solutions 
were stored at -80°C. 
 
5.2.2.7 Real-time RT-PCR 
The reverse transcription polymerase chain reaction (RT-PCR) is used detect 
expression of a specific gene. RT-PCR involves the use of gene-specific primers and 
reverse transcriptase to synthesize a cDNA sequence to the mRNA. The cDNA is 
then amplified by multiple rounds of polymerase-mediated transcription of this 
template cDNA. There are several types of RT-PCR and the most precise one in 
terms of quantification is the real-time RT-PCR method, which requires an automated 
system able to detect fluorescence induced during the RT-PCR reaction. During RT-
PCR, the expression of a certain gene can be deduced by comparing it to 
constitutively expressed genes, also known as "housekeeping" genes. 
cDNA synthesis was done in a 20 µl reaction mix starting with 1 µg of total RNA 
using the reverse transcription system of Promega (Madison, WI; 42 °C for 30 min; 
99 °C for 5 min, and 4 °C for 5 min). Real-time RT- PCR was performed using a 
LightCycler (Roche Diagnostics, Mannheim, Germany), and threshold cycle numbers 
were determined using the LightCycler software, version 3.5. DAPK primer 
sequences were sense 5’-CCTTGCAAGACTTCGAAAGGATA-3’ and antisense 5’-
GATTCCCGAGTGGCCAAA3’, the two hybridization probes were 
CTTAATTCTTGGCTGCAGGTTCTGTG-FL and LC Red640-
GTCGGAGCTGCTGGATGAAGAGTC-ph. P53 primer sequences were sense 5’-
ATGAGCCGCCTGAGGTTG-3’ and antisense 5’-
AGCTGTTCCGTCCCAGTAGATTA-3’, the two hybridization probes were 
GGCATGAACCGGAGGCCCA-FL and LC Red640- 
CCTCACCATCATCACACTGGAAGACTCC–ph. The real-time RT-PCR was 
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performed in a final volume of 20 µl. The final reaction mixture contained the forward 
and reverse primer at 10 pmol each, the LC Red640 probe at 40 pmol, the FL probe 
at 20 pmol, 4 mM MgCl2, and 1 x Master Amp hybridization mix. PCR was performed 
under the following conditions: 95 °C for 30 s, fol lowed by 45 cycles of 95 °C for 0 s, 
57 °C (DAPK) or 62 °C (p53) for 10 s, and 72 °C for  5 s. We used serial dilutions of 
the positive control cDNA of HCT116 cells to create a standard curve. PCR was 
performed in triplicate, and the threshold cycle numbers were averaged.  Fold 
induction was calculated according to the formula 2(Rt-Et)/2(Rn-En), where Rt is the 
threshold cycle number for the ß2-M gene in the treated cells, Et is the threshold 
cycle number for the experimental gene in treated cells, Rn is the threshold cycle 
number for the ß2-M gene in non-treated cells, and En is the threshold cycle number 
for the experimental gene in non-treated cells.  
 
5.2.2.8 Preparation of total protein from cells  
Whole-cell lysates were prepared from cell pellets and were lysed by the addition of 
protein lysis buffer containing 4 M Urea, 0.5% SDS, 62.2 mM Tris (pH 6.8), 1 mM 
PMSF, and 1:100 of Protease Inhibitor Cocktail Set III (Calbiochem). The cells were 
lysed by vortexing every 10 minutes in total time of 1 hour. The mixture was 
centrifuged at 14000 rpm at 4º C for 20 minutes to remove the cell debris. Cell 
lysates were stored at -80º C. Total protein concentration of the samples was 
determined as described below (5.2.2.9). 
 
5.2.2.9 Preparation of cellular extracts using RIPA buffer 
For Immunoprecipitation experiments, cells were lysed with RIPA buffer. During RIPA 
lysis intracellular and membrane proteins are solubilized due to the presence of 
detergent and high salt concentration in the lysis buffer. Nonsolubilized proteins are 
precipitated by centrifugation. Protease inhibitor cocktail is included in the lysis buffer 
to prevent proteolysis, phosphotase inhibitor cocktail - to maintain the 
phopsphorylation status of phosphoproteins, EDTA - to chelate divalent ions that are 
essential for metalloproteases. Cells (107) were washed twice with ice cold PBS, 
lysed with 1.5 ml RIPA buffer supplemented with the cocktail of 
protease/phosphotase inhibitors and incubated on ice for 15 minutes with occasional 
rocking. Lysates were then collected by centrifugation at 12000 rpm for 10 minutes at 
4°C. Cell lysates were than briefly sonicated. Cell s were incubated on ice for 10 min 
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and centrifuged at 12000 rpm at 4°C for 10 min. The  supernatant containing total 
cellular proteins was collected and stored at –20°C . Total protein concentration in the 
supernatant was determined as described below (5.2.2.10). 
 
5.2.2.10 Determination of protein concentrations 
Protein concentration was determined using Bio-Rad Dc Protein Assay (BioRad 
Laboratories, Hercules, CA). The Bio-Rad DC (detergent compatible) protein assay is 
a colorimetric assay for protein concentration following detergent solubilization. The 
reaction is similar to the well-documented Lowry assay (Lowry et al. 1951). The 
standard assay is used with samples having protein concentrations between 0.1 and 
2.0 mg/ml. After plating five µl of standards and protein laysates in duplicates into a 
96-well plate, 25 µl of (Reagent A and S) and 200 µl of Reagent B were plated to 
each well and incubated 15 minutes at room temperature. The Bio-Rad DC protein 
assay was measured at 650–750 nm with a microplate reader. A standard curve was 
prepared by plotting the average Blank-corrected 562 nm measurement for each 
BSA standard vs. its concentration in mg/ml. The standard curve was used to 
determine the protein concentration of each unknown sample. 
 
5.2.2.11 Immunoprecipitation of proteins from cellular lysates 
In this approach, specific antibody is added to the cellular lysate to bind protein of 
interest. Antibody-protein complexes are then precipitated using solid-phase matrix. 
Bacterial proteins A and G which have specific binding sites for Fc-parts of 
antibodies, covalently coupled to crosslinked agarose, are usually used as solid-
phase matrix to precipitate protein-antibody complexes. Samples were pre-cleared at 
4°C  for 1 h using protein G or A-Sepharose beads. Cellular lysates containing 0.5-1 
mg of total protein were mixed with about 1 µg of antibody in pre-chilled 1.5 ml tubes 
on ice. Volumes of the mixture were adjusted to 400-500 µl to obtain equal protein 
concentrations in each sample. Tubes were incubated overnight at 4°C with constant 
rotation. 70-75 µl of Protein A or G coupled agarose was added to each sample and 
tubes were incubated for additional 4 hours at 4°C with constant rotation. Following 
incubation with Protein A or G sepharose, immuno-complexes were pelleted by 
centrifugation at 12000 rpm at 4°C for 1 minute and  washed 3 times with ice-cold 
RIPA lysis buffer and one time with ice-cold wash buffer. Each time complexes were 
collected by centrifugation at 12000 rpm at 4°C for  1 minute. Five-10 µl of the wash 
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buffer used for the last wash were left above the agarose pellet. Thirty µl of 2X 
Laemmli loading buffer were added to the samples and proteins were denatured by 
heating to 95°C for 5 minutes. Samples were cooled down on ice and analyzed 
immediately or frozen at –20°C for later analyses. Protein A or G sepharose was 
pelleted by centrifugation at 12000 rpm at 4°C for 2 minutes and supernatants, 
containing immunoprecipitated proteins were analyzed by SDS-PAGE 
electrophoresis (5.2.2.13). 
 
5.2.2.12 In vitro kinase assay.  
The In Vitro Kinase Assay provides a simple and straightforward method to assay 
kinase activity without performing time-consuming transfections. This assay helps to 
determine whether the kinase of interest is able to phosphorylates its specific 
substrate. Immunoprecipitation carried out as described above as shown in Figure 6. 
Sepharose-bound immune complexes in lysis buffer were washed and resuspended 
in kinase buffer (60 mM HEPES, pH 7.5, 3 mM MnCl2, 3 mM MgCl2, 3 µM sodium 
orthovanadate, 1.2 mM DTT, 2.5 µg/µl PEG) before incubation with 7.5 µCi [ 32-P] 
ATP (GE Healthcare, Amersham Biosciences) and 2 µg RB-S6P (Biomol) at 25°C for 
80 min. Samples were boiled at 95°C for  5 min and separated on a 10% gel by SDS-
PAGE prior to autoradiography. 
 
Antibody •Lysate
•Immunopreciptate kinase
Antibody-kinase complex
Kinase substrate and 
protein of interest, buffer, 
[γ32-P] ATP
•Incubate for 30 min
•Run SDS-PAGE
Gel-exopsure to x-ray film.
 
FIG. 6. Principle of the in vitro kinase assay. 
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5.2.2.13 SDS-PolyAcrylamide Gel Electrophoresis 
In this approach proteins in the mixture are denatured by heating in the presence of 
DTT and SDS. Denatured polypeptides bind SDS and become negatively charged. 
The amount of bound SDS is almost always proportional to the molecular weight of a 
polypeptide, and is independent of its sequence. Therefore proteins and protein 
subunits are separated according to their size during migration through the pores in 
the gel matrix in response to an electrical field. The protein samples were mixed with 
5x loading puffer and with 2x loading puffer to achieve equal loading amounts. 
Proteins were boiled for 5 minutes for complete denaturation. This mixture was 
loaded along with the Biotinylated protein Ladder, which was heated at 99° C for two 
minutes. Separation gels with the following dimensions were used: thickness 1.0 mm, 
length 7.3 cm and width 8.3 cm. TEMED was used for the catalysis of the 
polymerization reaction, which was initiated by adding APS. The stacking gel was 
composed similar to the running gel, only Tris-HCl with pH 6.8 was used and the 
acrylamid had a final concentration of 3%. Proteins were separated at 30-50 mA until 
the dye front has reached the end of the separation gel. 
 
5.2.2.14 Transfer of proteins to Nitrocellulose membrane 
electrophoresed Immunoblotting was performed utilising the semi dry transfer 
method. Nitrocellulose membrane (Schleisser and Schuell, Germany) and 2 layers of 
2 papers were cut exactly to the size of the gel and soaked in transfer buffer, shown 
in figure 7. A stack was made with 2 papers on the top and bottom of the gel and 
membrane and placed in between the graphite plates of the transfer apparatus 
(Biometra, Germany). Transfer was performed at 17 V for 1 hour. In semi-dry blotting 
the electrodes are placed directly in contact with the gel/nitrocellulose membrane 
sandwich to provide a fast, efficient transfer. Because of this direct contact there is a 
minimum of transfer buffer required for this process. The membrane was soaked in 
transfer for a few minutes and then transferred to a container with Towbin transfer 
buffer. Gel and attached membrane were sandwiched between two pieces of 
Whatman paper and soaked in the transfer buffer. 
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FIG. 7. An exploded view of the Trans-Blot SD cell: 1, safety lid; 2, cathode 
assembly with latches; 3, filter paper; 4, gel; 5, membrane; 6, filter paper; 7, spring-
loaded anode platform, mounted on four guide posts; 8, power cables; 9, base. The 
prestained protein ladder served as a control for the transfer. 
 
5.2.2.15 Ponceau S staining of proteins on PVDF membrane 
Staining with Ponceau S was used to provide visiual evidence that electrophoretic 
transfer of proteins has taken place. Ponceau S is a negative stain which binds to the 
positively charged amino groups of the protein. The proteins bans were visiulized by 
incubating the membrane for 5-10 seconds in a 0.1% solution (containing 1% acetic 
acid) of Ponceau S staining solution. The excess stain was washed with TBST. 
 
5.2.2.16 Analysis of proteins by immunoblotting 
In this method, specific antibodies are used to identify proteins transferred to blotted 
membrane. First, membrane is immersed in blocking buffer to fill all protein binding 
sites with non-reactive protein. Then membrane is incubated in a solution containing 
antibody directed against the antigen(s) in the protein to be detected. Primary 
antibody bound to the protein of interest is recognized by secondary antobody 
conjugated with horseradish peroxidase (HRP). The complex containing the antigen, 
primary antibody and secondary antibody-HRP conjugate is detected by chem 
luminescent visualization using ECL detection system. The membranes were blocked 
in the blocking solution either for at lease one hour at room temperature. After 
blocking membranes were incubated with antibodies appropriately diluted in either 
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5% BSA or 5% milk blocking buffer in TBS-T overnight at 4°C with agitation. After 
incubation with primary antibodies, membranes were washed three times each 10 
minutes, then transferred to the containers with secondary antibody-HRP conjugates 
in 5% milk blocking buffer in TBS-T and incubated for 1 hour at room temperature 
shaking gently. Membranes were then rinsed twice and washed with agitation three 
times for 30 minutes. Bound antibodies were detected by incubating the blots in West 
Pico chemiluminescent substrate (Pierce, Rockford, IL). The level of 
immunoreactivity was then measured as peak intensity using an image capture and 
analysis system (GeneGnome, Syngene, UK). Hybridization with anti-β-actin was 
used to control equal loading and protein quality.  
 
5.2.2.17 Stripping and re-probing of western blot 
The blotted membranes were stripped and re-probed using Restore™ Western Blot 
Stripping Buffer. Twenty ml of Restore™ Western Blot Stripping Buffer were warmed 
to room temperature. Membranes were placed in the buffer to be stripped and 
incubated for 10 minutes at 42° C. After incubation , the blots were removed from the 
buffer and washed 2 times for 15 minutes in TBS-T. After determining that the 
membranes were properly stripped, next immunoprobing experiments were 
performed. 
 
5.2.2.18 siRNA transfection 
siRNA is sometimes known as short interfering RNA or silencing RNA, are a class of 
20-25 nucleotide-long double-stranded RNA molecules that play a variety of roles in 
biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway 
where the siRNA interferes with the expression of a specific gene. In addition to their 
role in the RNAi pathway, siRNAs also act in RNAi-related pathways. Small/short 
interfering RNA (siRNA) transfection is an exciting new method for introducing foreign 
genetic information by inducing RNA interference. siRNA works by silencing key 
sequences on messenger RNA, which turns off specific genes by cleaving to them on 
the RNA strand.  siRNA is dsRNA chemically cut into specific segments so that the 
entire strand or a portion of the dsRNA can cleave to the mRNA without causing a 
viral response, shown in figure 8. siRNA transfection is the introduction of the siRNA 
into the cell through chemical and biologic reagents. We followed the siRNA 
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transfection protocol of the manufacturer with only minor modifications (SantaCruz, 
USA). The optimal amount of siRNA was determined as 8 and/or 30 µl siRNA diluted 
in 6 µl transfection reagent were added together with transfection medium and 
incubated for 45 minutes in dark at room temperature. The mixture was add then to 
the cells for 6 hours. The cells were then assayed for different experiments. siRNA 
efficiency reached in the HCT116 cells a complete DAPK protein down-regulation 
and reduction of p38 protein level by 50%. In the U937 DAPK and RSK specific 
siRNA resulted in 50% protein reduction. 
 
 
•siRNA duplex
•‚Guide‘ to the nuclease complex
•‚Guide‘ to the homologous mRNA
•Target mRNA is degradated by nucleases
 
FIG. 8. Principle of siRNA transfection. 
 
5.2.3 Quantification of apoptosis 
5.2.3.1 Annexin V-binding and PI staining 
In the early stages of apoptosis, changes occur at the cell surface. One of these 
plasma membrane alterations is the translocation of phosphatidylserine (PS) from the 
inner side of the plasma membrane to the outer layer, exposing PS at the surface of 
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the cell. Macrophages specifically recognize PS exposed on the cell surface of 
lymphocytes during the development of apoptosis. The recognition and phagocytosis 
of apoptotic cells and bodies protects organisms from exposure to cellular 
compounds that lead to inflammation, which usually accompanies necrosis. Annexin 
V is a Ca2+-dependent phospholipid-binding protein with a high affinity for PS, making 
labeled annexin an excellent detection agent. 
To detect apoptosis the Annexin-V-FLOUS kit (Roche Diagnostics) was used. Cells 
stimulated for 24-72 hours with the above mentioned conditions. Growth media of the 
cells were collected and the cell were washed two times with PBS. Cells were then 
trypsinized and collected by centrifugation at 200xg for 15 minutes. 1x106 cells were 
stained with 100 µl annexin V staining solution, consisting of 20 µl fluorescein 
isothiocyanate (FITC)-conjugated annexin V reagent (20 µg/ml), 20 µl sotonic 
propidium iodide (50 µg/ml) and 1000 µl of 1 M HEPES buffer, for 15 min at room 
temperature. Cells were analyzed on a FACScan flow cytometer (Becton-Dickinson, 
CA, USA) using a 488-nm excitation and 515-nm band pass filter for fluorescein 
detection and a filter >600 nm for propidium iodide detection after electronic 
compensation. Since positive annexin V staining is seen for apoptotic and necrotic 
cells, propidium iodide-positive cells were used to measure late apoptotic and 
necrotic, whereas annexin V-positive and propidium iodide-negative cells were 
counted as early apoptotic cells.  
 
5.2.3.2 Caspase 3/7 activity assay 
The Caspase-Glo® 3/7 Assay is a luminescent assay that measures caspase-3  
and -7 activities in purified enzyme preparations or cultures of adherent or 
suspension cells. The assay provides a proluminescent caspase-3/7 substrate, which 
contains the tetrapeptide sequence DEVD. This substrate is cleaved to release 
aminoluciferin, a substrate of luciferase used in the production of light. The Caspase-
Glo® 3/7 Reagent has been optimized for caspase activity, luciferase activity and cell 
lysis. The addition of the single Caspase-Glo® 3/7 Reagent in an "add-mix-measure" 
format results in cell lysis, followed by caspase cleavage of the substrate and 
generation of a “glow-type” luminescent signal. The Caspase-Glo® 3/7 Assay is used 
for screening of caspase activity or apoptosis. Cells were seeded at in 96-well white-
walled plates and incubated overnight. After treatment, Caspase-Glo 3/7 reagent was 
added for 1.5 h. Caspase activity was analyzed using a luminometer and quantified 
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as relative light units according to manufacturer’s instructions. Caspase activation is 
shown as the ratio between the caspase activity of the treated sample and the activity 
of the corresponding untreated cells (relative caspase activity index). 
 
5.2.4 Enzyme-linked immunoassays 
5.2.4.1 Determination of human TNFα and IFNγ concentrations in cell culture 
supernates 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibodies specific for TNFα and IFNγ have been pre-coated onto a 96-
well microplate separately. Standards and samples are pipetted into the wells and 
any TNFα and IFNγ present are bound by the immobilized antibody. After washing 
away any unbound substances, an enzyme-linked polyclonal antibody specific for 
TNFα and IFNγ is added to the wells. Following a wash to remove any unbound 
antibody-enzyme reagent, a substrate solution is added to the wells and color 
develops in proportion to the amount of TNFα and IFNγ bound in the initial step. The 
color development is stopped and the intensity of the color is measured. The level of 
TNFα and IFNγ were measured in cell culture supernates collected at 1, 2, 3, 4, 8, 24 
h after stimulating with (1, 5, 10 ng/ml) LPS. The assay was performed according to 
the manufacturer’s recommendations. Absorbance at 450 nm was measured and 
corrected using the 540-nm reading on the microplate reader. TNFα and IFNγ 
contents were calculated according to the parameter of the calibration curve. 
Calibration curves with a correlation coefficient at least 0.998 were used. All 
experiments were replicated three times. 
 
5.2.4.2 p38 MAPK activity Assay 
The OmniaTM Plate-Based IP Kinase Assay Kit for p38 MAPK is designed to measure 
the kinase activity of p38 MAPK in cell lysates. This kit uses a p38 MAPK specific 
antibody to capture the target and separate it from the complex mixture of proteins in 
a crude cell lysate. The phosphotransferase (kinase) activity of the captured p38 
MAPK is measured by using a cascade reaction, which uses an inactive MAPKAPK2 
enzyme and a MAPKAPK2 substrate peptide (OmniaTM Ser/Thr Peptide 3). In the 
presence of ATP, the active p38 MAPK will phosphorylate and activate MAPKAPK2. 
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The activity of MAPKAPK2 is measured using a novel peptide substrate which 
contains the chelation-enhanced fluorophore, 8-hydroxy-5-(N,N-
dimethylsulfoanamido)-2-methylquinoline (referred to as SOX7) in a real-time kinetic 
measurement mode. Sox is an unnatural amino acid that can be prepared as an 
Fmoc protected derivative and has been incorporated into the MAPKAPK2 substrate 
peptide (OmniaTM Ser/Thr Peptide 3) using standard solid-phase peptide chemistry. 
Upon phosphorylation of the peptide by MAPKAPK2, Mg++ is chelated to form a 
bridge between the Sox moiety and the phosphate group that is added by 
MAPKAPK2 to the serine residue within the peptide, resulting in an instantaneous 
increase in fluorescence when the kinase reaction mixture is excited at 360 nm and 
the emission is measured at 485 nm8. The fluorescence intensity generated at a 
given time is directly proportional to the concentration of active p38 MAPK present in 
the sample. 100 µg of cell lysates (control or stimulated/treated) where plated in a 96-
well plate together with active p38 as a positive control. The unbound laysate was 
rinsed 4 times with wash buffer. The inactive substrate together with the reaction 
mixture were added to the bound p38. finally the plate was transferred to a 
fluorescent microplate reader. The measured values where adjusted to the controls.  
 
5.2.5 Immunohistochemical analyses 
5.2.5.1 Immunohistochemistry of paraffin embedded tissues 
5.2.5.1.1 Haematoxylin and Eosin staining 
Staining of the nucleus of the cells was done with haematoxylin; eosin was used for 
the cytoplasm staining. Samples were deparaffinized by incubation in xylene for 20 
min, 2 minutes in 100%, one minute in 96 %, one minute in 75% ethanol and finally 
washed in distilled water. The samples were then rinsed in haematoxylin for one 
minute, washed in distilled water and incubated with eosin for 2 minutes. After 
washing the slides were mounted with Mayer gel. 
 
5.2.5.1.2 Staining of DAPK and phosphp-p38 
Immunohistochemical studies were performed using the avidin-biotin complex 
immunostaining method and the automated immunohistochemistry slide staining 
system by Ventana NexES (Ventana Medical System, Strasbourg, France). 
Immunohistochemical studies were performed on 3 µm thick, formalin-fixed, paraffin-
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embedded serial tissue sections. Samples obtained from cases of methylated and 
unmethylated colorectal carcinoma (6 cases each) and 12 additional normal colon 
samples without pathological findings were analyzed for DAPK and phosphor-p38 
protein expressions. Formalin-fixed paraffin-embedded serial tissue sections (3 µm 
thick) were dewaxed in xylol and rehydrated by descending concentrations of 
ethanol. For antigen retrieval, pre-treatment was performed by microwave heating in 
1 mM sodium citrate puffer (30 minutes, 600 W, pH 6.0). Incubation of each one 
series with anti-DAPK (mouse monoclonal antibody, dilution 1:500, BD Transduction 
Laboratories, Heidelberg, Germany) and anti-Phospho-p38 MAPK (rabbit monoclonal 
antibody, dilution 1:100, Cell Signaling Technology, Boston, MA, USA) was 
conducted at room temperature for 12h and followed by PBS-washing. Positive 
immunohistochemical reactions were revealed using the iVIEWTM DAB Detection Kit 
(Ventana, Germany) as chromogen substrate. Specimens were counterstained with 
hematoxylin and mounted with DEPEX. Samples were examined by two different 
reviewers blinded to other data. 
 
5.2.5.2 Triple Immunofluorescence staining of cells 
Immunofluorescence staining methods are used successfully for labeling multiple 
antigens in the same preparation. These methods are especially useful for co-
localization of antigens in the same compartment of a cell. 
The co-localization of DAPK and phospho-p38 or RSK was carried out on cells. 
DAPK was stained with anti-DAPK (BD Transduction, Laboratories, Lexington NY), 
phospho-p38 (Cell Signalling. Technology Inc.), or RSK (Cell Signalling. Technology 
Inc) and nucleus with 4'-6-Diamidino-2-phenylindole (DAPI) Control and 
stimulated/treated, 2 x 105 cells, grown in 10% FCS in RPMI medium on 2 well 
chamber slides (Nunc, Germany) and were fixed in 3% paraformaldehyde for 15 min 
than permeabilized with 0.2% Triton X-100 for 5 min. Cells were blocked with 1% 
BSA for 10 min, and incubated with mouse anti DAPK antibody at 1:50 dilution 
overnight at 4°C, followed by incubation with Cy3 a nti-mouse secondary antibody 
(Sigma) at 1:400 dilution for 1 hour at room temperature. The subsequent reaction 
was carried out first by blocking step with 1% BSA than by incubating the cells with 
rabbit anti p-p38 or RSK at 1:1000 dilution for 2 hours at 37° C, followed by a 1:100 
dilution of Flourescein anti-rabbit secondary antibody (Vector Labs) for 1 hour at 
room temperature. The slides were counterstained and mounted with DAPI + 
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mounting medium (Vector Labs) and were examined under a fluorescence 
microscope equipped with the appropriate filters. 
 
5.2.6 Statistical analysis 
Data are presented as the means of triplicates from three separate experiments +/- 
SEM. Statistical comparisons of experimental data were performed by Student’s t 
test. The level of statistical significance was set at P<0.05.  
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6. Results 
 
 
6.1 DAPK status in different colorectal cell lines 
6.2 Macrophage                Tumor cell       
6.2.1 Macrophage-mediated killing of HCT116 p53+/+ tumor cells 
6.2.2 Macrophage-triggered up-regulation of DAPK expression  
6.2.3 Increase in TNFα and IFNγ release upon macrophage a
 ctivation 
6.2.4 TNFα but not IFNγ exposure induced apoptosis in HCT116 
p53+/+ cells  
6.2.5 TNFα mediated DAPK-dependent apoptosis in HCT116 p53+/+ 
cells. 
6.2.6 Early activation of p38 in HCT116 p53+/+ tumor cells 
subjected to TNFα.  
6.2.7 Identification of p-p38 as DAPK binding-protein  
6.2.8 Triggering of DAPK-mediated apoptosis by p-p38 
6.2.9 P53 acts down-stream of DAPK   
6.2.10 TNFα alone induced cell death in HCT116p53-/- 
6.2.11 P38 is also activated in the p53 deficient HCT116 cells upon 
TNFα exposure 
6.2.12 Physiological relevance of DAPK regulation 
6.2.12.1 DAPK co-localizes with p-p38 in human colorectal 
carcinoma 
6.2.12.2 Apoptosis induction in the HCT116 p63+/+ cell and 
DAPK up-regulation after exposure to the supernatants of 
freshly isolated activated human macrophages 
6.3 Tumor cell                 Macrophage 
6.3.1 Tumor cells-supernatants increased DAPK level but did not 
induce apoptosis in activated U937 
6.3.2 DAPK participated in survival of the activated macrophages 
6.3.3 RSK may be involved the DAPK-mediated cell survival of 
U937 
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6.1 DAPK status in different colorectal cell lines 
Based on the findings that DAPK is one of p53 target genes (Martoriati et al., 2005), 
we aimed to verify the expression of DAPK and p53 in five different colorectal cancer 
cell lines (HCT116 p53+/+, HCT116 p53-/-, HT29, CaCo, and SW480), using real-
time RT-PCR. As shown in Fig. 9A, no high correlation was found between DAPK 
and p53 transcripts in the normal status of the cell lines. This finding was further 
confirmed by analyzing protein levels of DAPK and p53, using Western Blotting (Fig. 
9B). To investigate the relationship between DAPK expression pattern and its  
methylation status, methylation-specific PCR (MSP) was performed to examine the 
status of methylation in the promoter of DAPK in the selected colorectal cell lines and 
in the macrophage-like cell line U937. Partial hypermethylation of DAPK promoter 
was observed in the two colorectal cancer cell lines (HCT116 p53-/- and SW489), but 
not in HCT116 p53+/+, HT29, and CaCo cell lines (Fig. 9C). DAPK was unmethylated 
in monocytic, differentiated and activated U937 (Fig. 9D). To investigate DAPK 
expression and its possible regulation by p53 and because p53 is mutated in HT29, 
CaCo and SW480, we selected HCT116 p53+/+ and its counterpart HCT116 p53-/- 
cell lines. 
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FIG. 9. DAPK status. (A) real-time RT-PCR analysis was performed using 
gene-specific primers for DAPK and p53. (B) Lysates prepared from five colorectal 
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cell lines were analyzed by anti-DAPK, anti-p53, or anti-ß-actin Western blotting for 
equal loading. (C) methylation status of DAPK promoter in five colorectal cell lines 
and different status of the macrophage-like cell line U937 (D). 
 
6.2 Macrophage                Tumor cell       
 
6.2.1 Macrophage-mediated killing of HCT116 p53+/+ tumor cells  
Schneider-Stock et al., 2006 showed that, DAPK protein expression in colorectal 
tumor cells and their tumor-associated macrophages was found to be highly 
correlated. Furthermore, the increase in the DAPK level was associated with higher 
apoptosis in colorectal tumor cells.  
To determine whether tumor-associated macrophages and their secretion of cytotoxic 
mediators might induce apoptosis in tumor cells, we used a cell culture assay to 
recapitulate events that might occur in the in vivo tumor setting. For this purpose, the 
conditioned media from the treated macrophage cell line U937 [differentiated with 
PMA (diffM) and differentiated + activated with LPS (actM)] were collected, filtered, 
and applied to HCT116 p53+/+ colorectal tumor cells. The apoptosis in tumor cells 
was assessed after 24-72 h of incubation with the macrophage-conditioned media, by 
Annexin-V-FITC binding, and after 48h by caspase-3/7 activity assays. There was a 
significant apoptosis induction (2.5-fold) in tumor cells treated with actM 
supernatants, starting early at 24 h (6.37% to 15.87%) and continuing until 72 h 
compared to untreated HCT116 p53+/+ cells (Fig. 10A). In contrast, diffM 
supernatants induced only an early increase in the percentage of apoptotic HCT116 
p53+/+ cells at 24 h (6.37% to 17.87%), but cell death disappeared at later time 
points (Fig. 10A). Considering the 48 h time point, these findings were in accordance 
with caspase activity data, showing 3-fold up-regulation in caspase 3/7 activity in 
HCT116 p53+/+ cells treated with actM supernatants (Fig. 10B). Thus, our data 
suggest that actM may release a soluble factor into the media, which might be 
responsible for apoptosis induction in HCT116 p53+/+ tumor cells. 
 
Results 
 - 51 - 
A
24 h
48 h
72 h
2.06% 4.38%
91.00% 2.56%
1.98% 4.07%
89.34% 4.61%
1.90% 5.98%
82.24% 9.89%
1.73% 9.43%
79.09% 9.75%
0.96% 7.29%
83.21% 8.54%
2.29% 9.17%
79.85% 8.7%
actM
sup.
diffM
sup.
Annexin-V
ctrl
0.65% 3.64%
92.98% 2.73%
Pr
o
pi
di
u
m
io
di
de
HCT116 p53+/+ B
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
ctrl diffM actM
sup.    sup.
3.5
HCT116 p53+/+ 
3.0
2.5
1.5
2.0
1.0
0.5
0.0
Pr
o
pi
di
u
m
io
di
de
Pr
o
pi
di
u
m
io
di
de
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
 
 
FIG. 10. Macrophages-induced cell death in HCT116 p53+/+ cells. (A) 
Annexin-V measurements of HCT116 p53+/+ cells (ctrl) and HCT116 p53+/+ cells 
subjected to diffM sup. or actM sup. for 24 h, 48 h, and 72 h. (B) HCT116 p53+/+ 
subjected to diffM sup. or actM sup. for 48 h were analyzed by caspase 3/7 activity 
assay. Ctrl, control; diffM sup., supernatant of PMA-differentiated macrophages 
U937; actM sup., supernatant of PMA-differentiated and PMA-activated 
macrophages U937. 
 
 
6.2.2 Macrophage-triggered up-regulation of DAPK expression.  
To investigate whether DAPK is involved in the observed apoptosis induction, we 
examined DAPK mRNA and protein expression. Real-time RT-PCR revealed that the 
steady state level of DAPK mRNA was unchanged during the experiment (Fig. 11A). 
However, there was an increase in the DAPK protein level even after 6 h of 
incubation with supernatants from diffM and actM (Fig. 11B). While the DAPK protein 
level was found to be increased only slightly at later time points after incubation with 
diffM supernatants, the DAPK protein level continued to increase markedly after 
incubation with actM supernatants, similarly to the time course of apoptosis induction 
(Fig. 10A). These data suggest that macrophage-mediated secretion of cytotoxic 
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factors by actM might induce DAPK protein accumulation without affecting its gene 
transcription.  
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FIG. 11. Macrophages up-regulate DAPK protein levels. (A) For HCT116 
p53+/+ cells, subjected to diffM sup. or actM sup., real-time RT-PCR analysis was 
performed using gene-specific primers for DAPK. (D) Lysates prepared from diffM 
sup.- and actM sup.-exposed HCT116 p53+/+ cells were analyzed by anti-DAPK, or 
anti-ß-actin Western blotting for equal loading. Control HCT116 p53+/+ cells served 
as control. Ctrl, control; diffM sup., supernatant of PMA-differentiated macrophages 
U937; actM sup., supernatant of PMA-differentiated and PMA-activated 
macrophages U937. 
 
6.2.3 Increase in TNFα and IFNγ release upon macrophage activation 
As earlier studies have shown that TNFα and IFNγ can promote DAPK-dependent 
apoptosis (Cohen et al., 1999; Deiss et al., 2001), they are potential candidates to be 
the cytotoxic factors secreted by actM in our experimental setting. Thus, we 
measured their release using an ELISA assay and determined the optimal time point 
and concentration of TNFα or IFNγ to be used in our further experiments.  
The diffM did not show any time-dependent TNFα or IFNγ release (Fig. 12A, B). In 
contrast, in actM (LPS 1 ng/ml, 5 ng/ml, and 10 ng/ml), concentrations of TNFα were 
significantly elevated (0 to 0.65 ng/ml), reaching a maximal release at 3 h, whereas 
IFNγ secretion (0 to 0.002 ng/ml) was only minor affected (Fig. 12A, B). Because 
both cytokines were significantly released by macrophages upon their activation, they 
were further investigated for their apoptosis-inducing effects in HCT116 p53+/+ cells.  
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FIG. 12. TNFα and IFNγ are significantly released by macrophage cell line 
U937 upon their activation. (A) U937 cells were stimulated with PMA or stimulated 
and activated with PMA and LPS, and subsequently, the supernatants were analyzed 
by TNFα-ELISA (A) and IFNγ-ELISA (B).  
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6.2.4 TNFα but not IFNγ exposure induced apoptosis in HCT116 p53+/+ cells  
We then proved whether TNFα or IFNγ exposure alone (measured in the supernatant 
upon LPS stimulation: 0.665 ng/ml or 0.002 ng/ml, Fig. 12) are capable of inducing 
apoptosis in HCT116 p53+/+ cells. IFNγ did neither alter the DAPK protein amounts 
during the time frame of 6 h to 72 h nor did it induce apoptosis (Fig. 13 A, B).  
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FIG 13. INFγ is not critical for macrophage-induced cell death in HCT116 
p53+/+ cells. (A) Lysates prepared from HCT116 p53+/+ cells subjected to 0.002 
ng/ml INFγ for 6 h, 24 h 48 h, and 72 h were analyzed by Western blotting using anti-
DAPK, or anti-ß-actin for equal loading. Control HCT116 p53+/+ cells (ctrl) served as 
control. (B) Annexin-V measurements of HCT116 p53+/+ cells (ctrl) and HCT116 
p53+/+ cells subjected to 0.002 ng/ml INFγ for 24 h, 48 h, and 72 h. 
In contrast, TNFα administration resulted in a significant increase in the apoptotic cell 
population in the Annexin-V assay (maximal induction at 48 h: 3.94% to 19.2% 
apoptotic cells) accompanied by 2.8-fold up-regulation in caspase 3/7 activity (Fig. 14 
A, B). Furthermore, TNFα exposure led to an elevated DAPK protein level in HCT116 
p53+/+ cells (Fig. 14C), paralleled by DAPK catalytic activity induction measured by 
in vitro kinase assay (Fig. 14D). In further studies we focused on signal transduction 
upon 0.665 ng/ml which best reflected the events that occurred in our experimental 
settings, albeit the same results were also revealed when using higher TNFα 
concentration [30 ng/ml (Cohen et al., 1999), 60, and 100 ng/ml]. These data indicate 
that TNFα is capable of inducing apoptosis and simultaneously activating DAPK.  
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FIG. 14. TNFα is critical for macrophage-induced cell death in HCT116 p53+/+ 
cells. (A) Annexin-V measurements of control HCT116 p53+/+ cells (ctrl) and 
HCT116 p53+/+ cells subjected to 0.665 ng/ml TNFα for 24 h, 48 h, and 72 h. (B) 
Control HCT116 p53+/+ cells (ctrl) and HCT116 p53+/+ cells subjected to 0.665 
ng/ml TNFα for 48 h were analyzed by caspase 3/7 activity assay. (C) Lysates 
prepared from HCT116 p53+/+ cells subjected to 0.665 ng/ml TNFα for 6 h, 24 h 48 
h, and 72 h were analyzed by anti-DAPK or anti-ß-actin Western blotting for equal 
loading. Control HCT116 p53+/+ cells (ctrl) served as control. (D) DAPK-
immunoprecipitate of HCT116 p53+/+ cells subjected to 0.665 ng/ml TNFα for 24 h 
was analyzed by in vitro kinase assay. DAPK-immunoprecipitate of control HCT116 
p53+/+ cells (ctrl) and IgG-immunoprecipitate subjected to 0.665 ng/ml TNFα served 
as controls. IP, immunoprecipitation; ctrl, control 
6.2.5 TNFα mediated DAPK-dependent apoptosis in HCT116 p53+/+ cells 
To verify if DAPK contributes to the observed TNFα-triggered cell death, we 
transfected the HCT116 p53+/+ cells with DAPK-specific siRNA, resulting in a 
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complete loss of DAPK protein expression after TNFα administration at 48 h where 
the maximal apoptosis induction was observed (Fig. 15A). Performing an Annexin-V 
assay, we found that apoptosis was markedly reduced in HCT116 p53+/+ cells, the 
DAPK expression of which was inhibited (Fig. 15B), suggesting a role of DAPK in 
TNFα-mediated cell death.  
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FIG 15. TNFα-induced apoptosis in HCT116 p53+/+ cells is mediated by 
DAPK (A) Lysates prepared from HCT116 p53+/+ cells knocked down for DAPK and 
subsequently subjected to 0.665 ng/ml TNFα for 48 h were analyzed by anti-DAPK or 
anti-ß-actin Western blotting for equal loading. HCT116 p53+/+ cells subjected to 
transfection reagent, DAPK-siRNA, and TNFα-treatment served as controls. (B) 
HCT116 p53+/+ cells were transfected with DAPK-siRNA, stimulated with 0.665 
ng/ml TNFα for 48 h and subsequently analyzed for apoptosis by Annexin-V 
measurements. Control HCT116 p53+/+ cells (ctrl), transfected HCT116 p53+/+ cells 
(DAPK-siRNA), and TNFα-exposed HCT116 p53+/+ cells (TNFα 48h) served as 
controls. ctrl, control; TR, transfection reagent. 
 
6.2.6 Early activation of p38 in HCT116 p53+/+ tumor cells subjected to TNFα  
Previous studies (Chen et al., 2005; Eisenberg-Lerner A et al., 2007) have revealed, 
that members of the MAPK kinase family (ERK, JNK) are involved in DAPK-
dependent apoptosis. To ascertain the role of ERK, JNK/SAPK, and p38 in TNFα- 
mediated apoptosis, we performed a western blot screen for the activation of these 
MAP kinases [total proteins and corresponding phosphorylated (activated) forms]. 
We found a time-dependent pattern of MAPK activation upon TNFα. The only marked 
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de novo induction was detected for p-p38 within 6 h after TNFα administration, and it 
disappeared at later time points (24, 48, 72 h). p-JNK/SAPK slightly increased at 6 h 
and dropped down to the basal level at later time points (Fig. 16). 
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FIG 16. Early activation of p38 in HCT116 p53+/+ cells after TNFα exposure. 
Lysates prepared from HCT116 p53+/+ cells subjected to 0.665 ng/ml TNFα for 6 h, 
24 h 48 h, and 72 h were analyzed by Western blotting using anti-p38, anti-p-p38, 
anti-ERK1/ERK2, anti-p-ERK1/ERK2, anti-JNK/SAPK, anti-p-JNK/SAPK, or anti-ß-
actin for equal loading. HCT116 p53+/+ cells (ctrl) served as control. 
 
 
To investigate whether JNK could affect the observed apoptosis in HCT116 p53+/+ 
cells we transfected the cells with JNK-siRNA in the presence or absence of TNFα.  
JNK siRNA knock down did not influence DAPK-dependent apoptosis in HCT116 
p53+/+ cells subjected to TNFα (Fig. 17A, B). Thus, JNK signaling upon TNFα 
exposure was not further considered. In contrast to p-JNK, p-ERK1/2 was only 
activated at 72 h (Fig. 16). This very late activation seems not to be associated with 
DAPK-dependent apoptosis induction and therefore the p-ERK1/2 pathway was 
excluded in further experiments. 
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FIG 17. TNFα-induced cell death in HCT116 p53+/+ cells is not mediated by 
JNK. (A) Lysates prepared from HCT116 p53+/+ cells knocked down for JNK and 
subsequently subjected to 0.665 ng/ml TNFα for 48 h were analyzed by anti-JNK, 
anti-p-JNK, or anti-ß-actin Western blotting. HCT116 p53+/+ cells stimulated with 
transfection reagent alone and in combination with DAPK-siRNA or single TNFα-
exposure served as controls together with unstimulated HCT116 p53+/+ cells. 
 
Altogether, these data suggest that p38 seems to be the major player in DAPK-
dependent apoptosis after TNFα exposure in HCT116 p53+/+ cells. This hitherto 
unknown early functional induction of p-p38 was further confirmed in a p38 activity 
ELISA assay (Fig. 18). For the first time, we identified p-p38 MAPK as target for 
TNFα-mediated apoptosis and the role of p38 in TNFα/DAPK mediated apoptosis 
was selected to be the subject for our further investigations.  
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FIG. 18. HCT116 p53+/+ cells (ctrl) or subjected to 0.665 ng/ml TNFa for 6 h 
and 24 h were assayed for p38 MAPK activity, the control was adjusted to one. 
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6.2.7 Identification of p-p38 as DAPK binding-protein  
To determine whether the p-p38 is interacting with DAPK, we first analyzed the 
localization of both proteins in HCT116 p53+/+ cells with or without TNFα. We 
selected the 6 h time point for co-immunofluorescence studies because p-p38 and 
DAPK were here simultaneously induced. In the absence of TNFα, DAPK was found 
in the cytoplasm of tumor cells, whereas p-p38 was not detectable in the cells. Upon 
TNFα exposure, both proteins were found to be co-localized in the cytoplasm of the 
HCT116 p53+/+ cells (Fig. 19A). The physical interaction between DAPK and p-p38 
was further confirmed by co-immunoprecipitation studies. Performing a reverse 
immunoprecipitation with the anti-DAPK antibody followed by immunoblotting with 
anti-p-p38 antibody in the HCT116 p53+/+ cells subjected to TNFα (Fig. 19B), p-p38 
was identified as DAPK-interacting protein. Altogether, our results strongly indicate p-
p38 as a new DAPK binding partner in HCT116 p53+/+ cells upon TNFα exposure. 
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FIG. 19. p-p38 is a direct interacting partner of DAPK during TNFα-induced 
apoptosis. (A) TNFα-induced co-localization of DAPK and p-p38 after 6 h was 
determined by fluorescence immunolabeling analysis using anti-DAPK, anti-p-p38, 
and DAPI. (B) HCT116 p53+/+ cells subjected to 0.665 ng/ml TNFα were lysed, and 
DAPK or p38 proteins were immunoprecipitated using anti-DAPK or anti-p-p38. 
Precipitates were analyzed by Western blotting for the presence of p-p38 and DAPK. 
IP, immunoprecipitation; ctrl, control. 
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6.2.8 Triggering of DAPK-mediated apoptosis by p-p38 
Having identified physical interaction between DAPK and p-p38, we then aimed to 
demonstrate the direct induction of DAPK catalytic activity by p-p38. For this, we 
used p38-siRNA to reduce the endogenous expression levels of p38 in HCT116 
p53+/+ cells upon TNFα exposure. siRNA transfection resulted in 50% reduction of 
p38 protein levels, but caused a complete suppression of p-p38 protein (Fig. 20A) 
and p38 activity (Fig. 20A). Furthermore, siRNA-mediated loss in p-p38 protein did 
not influence the DAPK protein level in cell lysates (Fig. 20B), but resulted in a 
significant repression of TNFα-induced DAPK catalytic activity (Fig. 20B) which was 
accompanied by an efficient loss of TNFα-induced apoptosis in HCT116 p53+/+ cells 
(Fig. 20C). Altogether, these results suggest that p-p38 may be necessary for DAPK-
activation and DAPK-mediated apoptosis in HCT116 p53+/+ cells upon TNFα 
exposure.  
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FIG. 20. TNFα-induced and DAPK-mediated apoptosis is triggered by p-p38. 
(A) Lysates prepared from HCT116 p53+/+ cells knocked down for p-38 and 
Results 
 - 61 - 
subsequently subjected to 0.665 ng/ml TNFα for 48 h were analyzed by Western 
blotting using anti-p38, anti-p-38, or anti-ß-actin for equal loading and were then 
assayed for p38 MAPK activity, the control was adjusted to 1.0. Control HCT116 
p53+/+ cells, HCT116 p53+/+ cells stimulated with transfection reagent, p38-siRNA, 
or TNFα served as controls. (B) DAPK-immunoprecipitate of HCT116 p53+/+ cells 
transfected with p38-siRNA prior to TNFα-exposure was analyzed by in vitro kinase 
assay. DAPK-immunoprecipitate of control HCT116 p53+/+ cells, of HCT116 p53+/+ 
cells transfected with p38-siRNA, or stimulated with transfection reagent or TNFα and 
IgG-immunoprecipitate subjected to 0.665 ng/ml TNFα served as controls. (C) 
HCT116 p53+/+ cells were transfected with p38-siRNA, subjected to 0.665 ng/ml 
TNFα for 48 h and subsequently analyzed for apoptosis by Annexin-V 
measurements. Control HCT116 p53+/+ cells (ctrl), transfected HCT116 p53+/+ cells 
(p38-siRNA), and TNFα-subjected HCT116 p53+/+ cells (TNFα 48h) served as 
controls. IP, immunoprecipitation; TR, transfection reagent. 
 
6.2.9 P53 acts down-stream of DAPK   
Recently, it was shown that p53 tumor suppressor is a DAPK upstream 
transcriptional regulator (Martoriati et al., 2005). Moreover, p53 is an effecter of 
DAPK-mediated apoptosis (Raveh et al., 2001).  To investigate the role of p53 in the 
observed apoptosis after application of conditioned supernatants of diffM and actM 
we compared HCT116 cells having different p53 status.  
Performing real-time RT-PCR in HCT116 p53+/+ cells, we did not find any alterations 
in the p53 transcript amounts in our experimental setting (Fig. 21A). Evaluating the 
Western Blots, the p53 protein expression level in the HCT116 p53+/+ cells first 
decreased at earlier time points (6h, 24h), but reached again the normal control 
expression level after 48h (Fig. 21B). This increase in p53 amounts, seen later, 
occurred with a time delay compared to the time course of DAPK protein increase 
(Fig. 11B). Investigating DAPK protein expression in HCT116 p53-/- cells subjected 
to the conditioned media of macrophages, we observed a similar pattern of DAPK 
protein amounts (Fig. 21C). Both findings suggest a down-stream action of p53. 
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FIG 21. p53 acts downstream of DAPK. (A) For HCT116 p53+/+ cells, 
subjected to diffM sup. or actM sup., RT-PCR analysis was performed using cDNA-
specific primers for DAPK. (B) Lysates prepared from diffM sup.- and actM sup.-
exposed HCT116 p53+/+ cells were analyzed by anti-p53 or anti-ß-actin Western 
blotting for equal loading. Control HCT116 p53+/+ cells served as control. (C) 
HCT116 p53-/- cells were subjected to diffM sup. or actM sup. and subsequently 
DAPK protein levels were analyzed by anti-DAPK or anti-ß-actin Western blotting for 
equal loading. Ctrl, control; diffM sup., supernatant of PMA-differentiated 
macrophages U937; actM sup., supernatant of PMA-differentiated and PMA-
activated macrophages U937. 
 
In the HCT116 p53-/- cells, apoptosis measured by caspase 3/7 activity and Annexin 
staining assays revealed a lower cell death induction (10%, at 48 h) in comparison 
with the HCT116 p53+/+ (20%, at 48 h) after incubation with diffM and actM 
supernatants (Fig. 22A, B) compared to the HCT116 p53+/+ cells. Both cell lines 
showed a reinforcement of apoptosis after exposure to the actM supernatant. These 
data suggest that the observed apoptosis induction may partly be strengthened by 
p53. 
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FIG. 22.The DAPK-induced apoptosis is partially p53-dependent. (A) Annexin-
V measurements of HCT116 p53-/- cells (ctrl) and HCT116 p53-/- cells subjected to 
diffM sup. or actM sup. for 24 h, 48 h, and 72 h. (B) HCT116 p53-/- cells subjected to 
diffM sup. or actM sup. for 48 h were analyzed by caspase 3/7 activity assay.  Ctrl, 
control; diffM sup., supernatant of PMA-differentiated macrophages U937; actM sup., 
supernatant of PMA-differentiated and PMA-activated macrophages U937. 
6.2.10 TNFα induced cell death in HCT116 p53-/- 
In the HCT116 p53-/- cells, TNFα induced early DAPK protein expression (6 h) which 
further increased till 72 h. this effect was accompanied by apoptosis induction  but to 
a much lesser extent (9%, at 48 h) than in the p53+/+ cells (20%, at 48 h) (Fig. 23). 
As mentioned above, these data again suggest that p53 acts downstream of DAPK 
and participates in the observed TNFα-mediated cell death. Altogether, having 
differences in the annexin positive cells but relatively the same caspase 3/7 activity in 
HCT116 p53+/+ and HCT116 p53 -/- cells, suggest another apoptosis pathway in the 
HCT16 p53 deficient cells. 
Results 
 - 64 - 
 
HCT116 p53-/- 
 
β-actin
DAPK
Ctrl 6h       24h       48h      72h
TNFα
TNFα 48h TNFα 72hctrl
Pr
o
pi
di
u
m
io
di
de
TNFα 24h
0.2% 0.9%
96.2% 2.6%
0.6% 3.0%
91.1% 5.2%
0.5% 3.0%
90.0% 6.4%
1.3% 4.0%
89.2% 4.8%
0
0.5
1.0
1.5
2.0
2.5
3.0
ctrl TNFα
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
A
B C
Annexin-V
Pr
o
pi
di
u
m
io
di
de
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
 
 
FIG. 23. TNFα-induced cell death in HCT116 p53-/- cells is accompanied by 
DAPK up-regulation. (A) Lysates prepared from HCT116 p53-/- cells subjected to 
0.665 ng/ml TNFa for 6 h, 24 h 48 h, and 72 h were analyzed by Western blotting, 
using anti-DAPK, or anti-ß-actin for equal loading. Control HCT116 p53-/- cells (ctrl) 
served as control. (B) Annexin-V measurements of unstimulated HCT116 p53-/- cells 
(ctrl) and HCT116 p53-/- cells subjected to 0.665 ng/ml TNFα for 24 h, 48 h and 72 h. 
(C) HCT116 p53-/- cells (ctrl) and HCT116 p53-/- cells subjected to 0.665 ng/ml 
TNFα for 48 h were analyzed by caspase 3/7 activity assay. 
 
 
6.2.11 P38 is also activated in the p53 deficient HCT116 cells upon TNFα 
exposure 
To investigate whether p38 is activated in HCT116 p53-/- after TNFα administration, 
we performed Western Blotting of p38 and its phosphorylated form. Indeed, our 
analysis showed an increase in the p-p38 protein level at 6 h and its activity (Fig. 
24A, B). Furthermore, double immunofluorescence analysis revealed a co-
localization of DAPK and p-p38 in the cytoplasm of HCT116 p53-/- cells upon TNFα 
exposure (Fig. 24C). 
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FIG. 24. Early activation of p38 and co-localization with DAPK in HCT116 p53 
deficient cells after TNFα exposure. (A) Lysates prepared from HCT116 p53-/- cells 
subjected to 0.665 ng/ml TNFα for 6 h, 24 h, 48 h, and 72 h were analyzed by 
Western blotting using anti-p38, anti-p-p38, or anti-ß-actin for equal loading. HCT116 
p53-/- cells (ctrl) served as control. (B) HCT116 p53-/- cells (ctrl) or subjected to 
0.665 ng/ml TNFα for 6 h and 24 h were assayed for p38 MAPK activity, the control 
was adjusted to 1.0. (C) TNFα-induced co-localization of DAPK and p-p38 after 6 h 
was determined by fluorescence immunolabeling analysis using anti-DAPK, anti-p-
p38, and DAPI. 
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6.2.12 Physiological relevance of DAPK regulation 
6.2.12.1 DAPK co-localizes with p-p38 in human colorectal carcinoma 
To investigate the physiological distribution of DAPK and p-p38 proteins, we 
performed an immunohistochemical analysis of the two proteins in serial sections of 
representative samples of normal colonic mucosa and colorectal carcinoma tissue 
with and without DAPK promoter methylation. As shown in Fig. 25, in the 
unmethylated tumors, the expression of DAPK was strongly associated with the 
presence of p-p38 expression. In contrast, the methylated carcinomas demonstrated 
a weak cytoplasmic p-p38 expression of the tumor with a nuclear expression of single 
tumor cell. In normal colorectal mucosa, nuclear expression of phospho-p38 MAPK 
was observed in the proliferative zone of the crypts was observed. 
 
FIG. 25. DAPK co-localizes with p-p38 in human colorectal carcinoma. 
Immunohistochemical analysis of DAPK and p-p38 in normal colonic mucosa and 
colorectal carcinoma tissue with and without DAPK promoter methylation was 
detected by anti-DAPK and anti-p-p38. (Microscope: Zeiss Axioscope 50, camera: 
Nikon coolpix 990; magnification: x200, x400) 
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6.2.12.2 Apoptosis induction in the HCT116 p63+/+ cell and DAPK up-regulation 
after exposure to the supernatants of freshly isolated activated human 
macrophages 
To gain further insight into the physiologic role of human macrophages, we 
stimulated the freshly isolated human macrophages with 10 ng/ml LPS, which 
induced TNFα release (0.352 ng/ml). Applying the activated macrophages-
supernatants to the HCT116 p53+/+ cells up-regulated DAPK protein levels and 
induced p-p38 already at 6 h (Fig. 26). Simultaneously, as a sign of apoptosis 
induction, caspase 3 cleavage was detectable. 
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FIG. 26. Lysates from human actM spernatant-stimulated HCT116 p53+/+ 
were analyzed by anti-DAPK, anti p-P38, anti-Caspase3 and anti-β-actin Western 
blotting. Unstimulated HCT116 p53+/+ served as control.
 
6.3 Tumor cell                 Macrophage  
6.3.1 Tumor cell-supernatants increased DAPK level but did not induce 
apoptosis in activated U937 
Schneider-Stock et al. (2006) showed that, by analysing human colorectal tumor 
sections, although DAPK levels were increased in the tumor-associated 
macrophages, no cell death was detected. Therefore, we aimed to test whether our 
experimental settings might recapitulate the in vivo observed events. Indeed, DAPK 
protein levels were increased after incubation the diffM and actM with either HCT116 
p53+/+ or HCT116 p53-/- supernatants (Fig. 27A, B). Furthermore, no p53 protein 
expression was detected. Moreover, in contrast to the diffM the supernatants of 
HCT116 cells did not induce apoptosis in actM (Fig. 28A). The observed apoptosis 
resistance in the actM was further confirmed by measuring the caspase activity (Fig. 
Results 
 - 68 - 
28B). Altogether, these findings indicate that DAPK might play a role in macrophages 
survival in a p53-independent pathway. 
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FIG. 27. Tumor cells-supernatants induced DAPK up-regulation in the 
macrophage-like cell line U937. (A) Lysates prepared from diffM and actM exposed 
to supernatants of HCT116 p53+/+ (A) or HCT116 p53-/- (B) cells were analyzed by 
anti-DAPK, anti-p53 or anti-ß-actin Western blotting for equal loading. diffM; PMA-
differentiated macrophages U937; actM; PMA-differentiated and LPS-activated 
macrophages U937, HCT116 p53+/+ sup.; supernatants of  HCT116 p53+/+, and 
HCT116 p53-/- sup.; supernatants of  HCT116 p53-/-. 
 
Results 
 - 69 - 
actM
0.4% 5.6%
88.5% 3.2%
0.50% 6.6%
86.9% 3.1%
0.4% 5.7%
89.0% 2.7%
1.9% 4.5%
92.2% 2.0%
0.8% 3.7%
94.1% 1.2%
diffM
0.5% 2.2%
95.9% 1.2%
HCT116p53+/+ sup.
0.5% 5.7%
87.7% 2.9%
0.9% 6.3%
87.6% 3.1%
2.2% 6.0%
89.9% 2.53%
0.8% 4.2%
93.1% 1.8% 24h
48h
HCT116p53-/- sup.
Pr
o
pi
di
u
m
io
di
de
Annexin-V
A
Pr
o
pi
di
u
m
io
di
de
0
0.5
1.0
1.5
2.0
2.5
3.0
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
diffM +         +        +        + 
actM - +         - +
HCT116p53+/+ sup.  - - +        +
0
0.5
1.0
1.5
2.0
2.5
3.0
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
diffM +       +         +        + 
actM - +         - +
HCT116p53-/- sup.   - - +        +
B
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
X-
fo
ld
ac
tiv
ity
o
f c
a
sp
a
se
s
3/
7
 
FIG. 28. Tumor cell-supernatants did not induce cell death in the activated 
macrophages. (A) Annexin-V measurements of diffM and actM subjected to the 
supernatants of HCT116 p53+/+ or HCT116 p53-/- for 24 h and 48 h. (B) diffM and 
actM subjected to the supernatants of HCT116 p53+/+ or HCT116 p53-/- for 48 h 
were analyzed by caspase 3/7 activity assay. diffM; PMA-differentiated macrophages 
U937; actM; PMA-differentiated and LPS-activated macrophages U937, HCT116 
p53+/+ sup.; supernatants of  HCT116 p53+/+, and HCT116 p53-/- sup.; 
supernatants of  HCT116 p53-/-. 
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6.3.2 DAPK participated in survival of the activated macrophages. 
Jin et al. (2005) demonstrated that, after overexpressing mouse DAPK β in HEK 
cells, it did not induce apoptosis and inhibited caspase 3 acitivty, suggesting an 
antiapoptotic effect of DAPK. In order to test if there is a relationship between the 
macrophages survival and DAPK up-regulation, siRNA to DAPK was used to 
suppress its expression in U937 subjected to HCT116 p53+/+ supernatants. As 
shown in fig. 29A there was a reduction of DAPK protein after siRNA transfection. 
Moreover, DAPK-siRNA transfected cells underwent apoptosis via reduction of BCL-
2 potein expression and induction of Bax levels and the cleavage of caspase 3 (Fig. 
29A). Application of DAPK-siRNA to actM exposed to HCT116 p53+/+ supernatants 
resulted in marked increase of apoptotic cells (Fig. 29B), indicating that DAPK is 
involved in the observed apoptosis resistance in the actM. 
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FIG 29. Cell survival in activated macrophages is mediated by DAPK. (A) 
Lysates prepared from U937 cells knocked down for DAPK and subsequently 
subjected to HCT116 p53+/+ were analyzed by anti-DAPK, anti-Bcl-2, anti-Bax, anti-
caspase 3, or anti-ß-actin Western blotting for equal loading. U937 cells subjected to 
transfection reagent, DAPK-siRNA, and HCT116 p53+/+ supernatants served as 
controls. (B) U937 were transfected with DAPK-siRNA, subjected to HCT116 p53+/+ 
supernatants for 48 h and subsequently analyzed for apoptosis by Annexin-V 
measurements. diffM; PMA-differentiated macrophages U937; actM; PMA-
differentiated and LPS-activated macrophages U937, HCT116 p53+/+ sup.; 
supernatants of  HCT116 p53+/+. 
 
6.3.3 RSK may be involved the DAPK-mediated cell survival of U937 
Recently, it has been demonstrated that RSK phosphorylates DAPK, resulting in 
inhibiting its pro-apoptotic function (Anjum et al., 2005). Therefore, we aimed to 
analyze RSK protein level and whether it participates in the observed DAPK-
mediated cell survival. Western Blotting analysis showed an increase of RSK protein 
levels (Fig. 30A). Moreover, performing double immunofluorescence revealed a co-
localization of RSK and DAPK in U937 cells (Fig. 30B), suggesting that RSK may 
participate in the macrophage apoptosis resistance. 
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FIG. 30. RSK is up-regulated and co-localized with DAPK in U937. (A) Lysates 
prepared from diffM and actM exposed to supernatants of HCT116 p53+/+ cells were 
analyzed by anti-RSK, or anti-ß-actin Western blotting for equal loading. (B) Co-
localization of DAPK and p-p38 after 6 h was determined by fluorescence 
immunolabeling analysis using anti-DAPK, anti-RSK, and DAPI. diffM; PMA-
differentiated macrophages U937; actM; PMA-differentiated and LPS-activated 
macrophages U937, HCT116 p53+/+ sup.; supernatants of  HCT116 p53+/+. 
 
Discussion 
 - 73 - 
 
7. Discussion 
 
 
There are a number of different methods used to treat cancer. Surgery, radiation and 
chemotherapy are three common forms of cancer treatment that have been used for 
a number of years. Recently, new strategies have been developed toward new 
therapeutic cancer approaches, namely immunotherapy. 
The concept of immunotherapy is based on the body's natural defense system, which 
protects the human body against a variety of diseases. Although we are less aware 
of it, the immune system also works to aid our recovery from many illnesses. For 
many years, physicians believed that the immune system was effective only in 
combating infectious diseases caused by such invading agents as bacteria and 
viruses. More recently, we have learned that the immune system may play a central 
role in protecting the body against cancer and in combating cancer that has already 
developed. This latter role is not well understood, but there is evidence that in many 
cancer patients the immune system slows down the growth and spread of tumors. 
The body's ability to develop an immune reaction to tumors may help determine 
which patients are cured of cancer using conventional therapies, including surgery, 
radiation and drugs. One immediate goal of research in cancer immunology is the 
development of methods to harness and enhance the body's natural tendency to 
defend itself against malignant tumors. Immunotherapy represents a new and 
powerful approach in anticancer treatment. Immunotherapy seems to offer great 
promise as a new dimension in cancer treatment, but it is still very much in its 
infancy. Immunotherapies involving certain cytokines and antibodies have now 
become part of standard cancer treatment (Senzer et al., 2004, Ribas et al., 2005 
Mazzolini et al., 2007). Other examples of immunotherapy remain experimental. 
Although many clinical trials of new forms of immunotherapy are in progress (Keilholz 
et al., 1997, Rubin et al., 1997, Morse et al., 1999), an enormous amount of research 
remains to be done before the findings can be widely applied. In this respect, 
targeting immune cells around tumors might be a promising approach in finding new 
alternatives of cancer treatments with less side affects.  
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The purpose of this study was to recapitulate the events observed by Schneider-
Stock et al., (2006), to investigate the role of DAPK in tumor cells and macrophages, 
including apoptosis and survival, and to study which mechanisms involve DAPK 
regulation. 
The current study identifies p-p38 MAPK as a novel interacting protein of DAPK 
during TNAα-induced apoptosis in colorectal cancer cells. p38 MAPK phoshorylation 
was found to be an upstream target for DAPK after TNFα exposure, providing new 
insights into the regulation of DAPK-mediated apoptosis. P-p38 regulates TNFα-
mediated cell death by enhancing DAPK catalytic activity. The DAPK/p-p38 
interaction was also evident in DAPK-unmethylated human colorectal cancer tissue. 
Furthermore, the physiological significance of our findings was verified by showing an 
increase in DAPK and p-p38 protein expression, as well as enhanced cell death after 
treatment of colorectal cancer cells with the conditioned supernatants of human 
freshly isolated and differentiated PBMCs.  
The experimental setting was based on our previous findings which showed that the 
higher apoptotic rate in colorectal tumors was associated with an increase in DAPK 
protein expression (Schneider-Stock et al., 2006). Interestingly, the DAPK protein 
expression was similar between macrophages and tumor cells, suggesting a cross 
talk between these two cell types in DAPK-mediated tumor cell death (Schneider-
Stock et al. 2006). To understand the effects that macrophages may have on 
colorectal cancer cells and DAPK expression, we developed a human cell culture 
model that simulates the physiologic conditions. Culture supernatants from diffM and 
actM macrophages were applied to the HCT116 colorectal tumor cell line. Our 
findings indicate that actM induced apoptosis in the tumor cells. In contrast, diffM 
(non-activated macrophages) were not able to mediate cell death in HCT116 cells. 
The observed cell death was associated with accumulation of DAPK protein rather 
than its gene transcription. As p53 was shown to transcriptionally transactivate the 
DAPK promoter in MEFs after tamoxifen treatment (Martoriati et al. 2005), we 
exclude this pathway for TNAα-driven, DAPK-dependent apoptosis. P53 also acts as 
a downstream effector of DAPK, contributing to an oncogene-driven p19ARF-
dependent checkpoint pathway (Raveh et al., 2001). The marginally lower apoptotic 
rate in the HCT116 p53-/- cells indicated that the TNFα-driven DAPK-dependent 
apoptosis was at least partially p53-dependent. This seems to be interesting against 
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the background of the fact that most of colon cancers bear p53 mutations that 
functionally inactivate the p53 protein and thus should be of therapeutical relevance. 
The complex between both kinases may be regulated in a phosphorylation-
dependent manner. P-p38 is known to phosphorylate its downstream targets at Ser 
and Thr residues. Activated p38 has been shown to phosphorylate several cellular 
targets, including transcription factors ATF1 and ATF2, MEF2A, Sap-1, NfkB, and 
p53 (Kyriakis and Avruch, 2001). For DAPK, activating and inactivating 
phosphorylation sites have been identified, but the endogenous DAPK status was 
never investigated: Chen et al. (2005) have shown that activated ERK 
phosphorylates DAPK at Ser735 after serum stimulation in HEK293T cells. On the 
other hand, RSK inactivates DAPK through phosphorylation at Ser289 after PMA 
exposure in HEK293E cells (Anjum et al. 2005). Recently, Wang et al. (2007) 
identified DAPK as a phosphorylation target of both tyrosine kinase Src and 
phosphatase LAR, which act in synergism to inactivate DAPK. In the case of p-p38, 
the activation of DAPK seems to have an apoptosis-promoting function. On way of 
p38-DAPK interaction is phosphorylation of DAPK by p38, thus enhancing its kinase 
activity. We found that p38 activation induces DAPK catalytic activity. Notably, DAPK 
possesses a serine-containing peptide (at Ser735) that can be phosphorylated by p38 
(for details see: www. scansite.mit.edu/cgi-bin/motifscan_seq). It is not clear which 
region of p-p38 interacts with DAPK domains. What is known is that p38 MAPK and 
ERK2 bind to D-domain peptides through a specific docking groove (Chang et al. 
2002, Lee et al. 2004). Chen et al. (2005) reported that DAPK interacts with ERK 
through a D-domain within its death domain and promotes the cytoplasmic retention 
of ERK, thereby inhibiting ERK signaling in the nucleus. The significance of the death 
domain of DAPK in mediating its death-promoting function after TNFα exposure was 
documented by Cohen et al. (1999). In our experimental setting, endogenous DAPK 
was found to co-localize with p-p38 MAPK in the cytoplasm after TNFα exposure in 
colorectal cancer cells. Without the stimulus, p-p38 was not detectable in the nucleus 
or in the cytoplasm of the cancer cells. Most stimuli that activate p38 also activate 
JNK, as we have observed upon TNFα exposure in colon cancer cells. Nevertheless, 
for our scenario, JNK activation was not found to play a role in DAPK-dependent 
apoptosis upon TNFα exposure.  
P38 was shown to be present in both the nucleus and cytoplasm of quiescent cells, 
but upon cell stimulation, the cellular localization of p38 is not well understood. Some 
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evidence suggests that following activation, p38 translocates from the cytoplasm to 
the nucleus (Raingeaud et al. 1995), but other data indicate that activated p38 is also 
present in the cytoplasm of stimulated cells (Ben-Levy et al. 1998). To the best of our 
knowledge, there is no report on p38 activation in the cytoplasm upon TNFα 
exposure. Here, we show for the first time an interaction of activated p38 MAPK and 
DAPK in the cytoplasm of TNFα-stimulated tumor cell death. 
Furthermore, TNFα induces p38 activation and apoptotic cell death in endothelial 
cells through downregulation of the Bcl-x(L) protein (Grethe et al., 2004). Similarly, 
for the TNFα-induced DAPK-dependent apoptosis, it was verified that DAPK acts 
upstream of caspase 3, and that the death-promoting effects of DAPK are 
counteracted by Bcl2. The novel finding of our experimental setting is that we 
connect these previous studies by showing that TNFα induces a DAPK-dependent 
caspase-associated apoptosis by interacting with activated p38 MAPK in colon 
cancer cells.  
Tumor-associated macrophages (TAMs) represent a prominent component of the 
leucocytic infiltrate in most malignant tumors (Balkwill and Mantovani, 2001). TAMs 
support tumor growth by secreting factors such as cytokines and matrix 
metalloproteases that promote proliferation, invasion, and metastasis of tumor cells 
as well as tumor vascularization (Sunderkotter C et al., 1994). In contrast, TAM-
derived inflammatory cytokines including TNFα, IFNγ, or TGFβ can also induce 
apoptosis in tumor cells (Baron-Bodo et al., 2005; Karpoff et al., 1996; Ohta et al., 
1996). We identified TNFα, but not IFNγ in supernatants derived from actM and diffM 
as the critical mediator for DAPK-dependent apoptosis in colon cancer cells. In our 
experimental setting, DAPK was up-regulated only at the posttranscriptional level. 
Therefore, TGF-β was excluded as a possible mediator, because it was found to 
transcriptionally activate DAPK through Smad binding-sites in its promoter (Jang et 
al., 2001).  
In contrast to our observations in the colorectal cancer cells, we showed that DAPK 
up-regulation in the activated macrophage-like cell line U937 was not associated with 
cell death, confirming the findings reported by Schneider-Stock et al. (2006). ActM 
showed cell death resistance even after incubation with supernatants of HCT116 p53 
wild type and deficient cells. Jin et al. (2005) demonstrated that, overexpressing 
mouse DAPK β in HEK cells did not induce apoptosis, by inhinbiting caspase 3 and 9 
activity and delaying cytochrome C release. In our study we demonstrated that the 
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survival in the actM was mediated by DAPK. Furthermore, we showed the 
mechanism of action in which DAPK triggered cell survival, by inhibiting caspase 3 
cleavage. It has been found that RSK inactivates DAPK-proapoptotic function (Anjum 
et al. 2005). Interestingly, RSK was up-regulated during differentiation and activation 
of macrophages. Moreover, RSK was co-localized with DAPK in the cytoplasm of the 
macrophages, suggesting that RSK may interact with DAPK and positively regulate 
the DAPK-antiapoptotic function. However, further studies has to be done, in order to 
clarify that exact mechanisms involved DAPK regulation and its role in cell survival 
and cytokines production in macrophages. 
TNF-α has long been recognized as an agent capable of inducing marked tumor 
regression and has undergone considerable testing against tumors in patients and 
animal models. Local administration of TNF-α alone, or in combination with other 
drugs or cytokines, was effective at inhibiting tumor growth with minimal side effects 
in both tumor models and human patients (Baisch etl al., 1990; Asher et al., 1991; 
Lasek et al., 1995 ,1996; Lejeune et al., 1994). Our study showed the cytotoxic 
potential of TNFα released from activated macrophages on colon cancer cells. We 
demonstrated the TNFα mechanism of action on p38 MAPK activation, which in turns 
induced DAPK activity and triggered apoptosis in colon cancer cells. Our In vivo 
examinations confirmed this DAPK-regulatory circuit.  
Taken together, further studies are required to define more precisely the interactions 
between the tumor-associated macrophages (TAMs) and their growing solid tumors. 
A better understanding of the regulation and function of TAMs or their secretory 
cytokines may help to establish more therapeutically efficacious novel therapies for 
cancer management. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 - 78 - 
8. Summary 
 
In summary, using our in vitro model, we could recapitulate the in vivo events 
observed by Schneider-Stock et al. (2006). We addressed that, colon tumor cells 
incubated with activated supernatants showed DAPK protein accumulation and 
underwent apoptosis. In contrast, although DAPK protein level was elevated after 
incubating the activated macrophages with colon tumor cell-supernatants, cells were 
apoptosis resistant. Moreover, we suggest that RSK may participate in the DAPK-
dependent cell survival in U937 cell line. We show that in vitro DAPK and apoptosis 
inductions were due to TNFα release from the macrophages. For the first time, we 
showed a co-localization and physical interaction between activated p38 MAPK and 
DAPK, a complex that triggers TNFα-mediated apoptosis in colorectal cancer cells. 
Finally, our study demonstrated the Physiological significance of DAPK regulation in 
colon cancer. Altogether, these results encourage further testing of TNFα for its role 
as an anti-cancer agent. 
 
Our results of can be summarized as follows: 
 
1- Macrophage                Tumor cell       
 
• Supernatants of activated macrophages mediated killing of HCT116 p53+/+ 
tumor cells.  
 
• Supernatants of activated macrophages triggered DAPK protein accumulation 
rather than affecting its gene transcription in HCT116 p53+/+ tumor cells.  
 
• Increase in TNFα and IFNγ release upon macrophage activation. 
 
• TNFα but not IFNγ exposure induced cell death and DAPK protein up-
regulation in HCT116 p53+/+ cells.  
 
• TNFα mediated DAPK-dependent apoptosis in HCT116 p53+/+ cells. 
 
• TNFα induced early activation of p38 in HCT116 p53+/+ tumor cells.  
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• JNK and ERK1/ERK2 did not contribute to TNFα/DAPK-triggered apoptosis in 
HCT116 p53+/+ cells. 
 
• P-p38 co-localized and interacted with DAPK, thus it is identified as a new 
DAPK binding-protein  
 
• P-p38 induced DAPK catalytic activity, thus it triggers the DAPK-mediated 
apoptosis by p-p38 
 
• P53 acted down-stream of DAPK and involved partially in the observed cell 
death.  
• TNFα induced apoptosis in HCT116 p53 deficient cells. 
 
• P-p38 was up-regulated in the p53 deficient HCT116 cells upon TNFα 
exposure. 
• P-p38 co-localized with DAPK in primary human colon cancer tissues. 
• Supernatants of freshly isolated activated human macrophages up-regulated 
DAPK, induced early activation of p38 and cleavage of caspase 3. 
 
2- Tumor cell                 Macrophage  
 
• HCT116 p53 wild type and deficient cells-supernatants increased DAPK level 
but no apoptosis was indicated in the activated U937. 
 
• DAPK was found to contribute to the cell survival of the activated 
macrophages, by inhibiting caspase-3 cleavage. 
 
• RSK co-localized with DAPK in the macrophage-like-cell line U937, thus it may 
play a role in the observed macrophages DAPK-mediated apoptosis 
resistance. 
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10. Abbreviations 
 
 
      
APS     Ammonium-persulfate………………………………… 
ATCC    American Type Culture Collection 
ATF    Activating transcription factor………………………… 
ATP     Adenosine triphosphate 
BSA     Bovine serum albumine……………………………….. 
cDNA    Complementary deoxyribonucleic acid 
CGI    CpG island……………………………………………… 
Da    Dalton 
DAPK    Death associated protein kinase…………………….. 
DAPI     4',6-diamino-2-phenylindole 
DMEM    Dulbecco's modified Eagles medium………………... 
DMSO    Dimethylsulfoxide 
DNA     Deoxyribonucleic acid…………………………………. 
DRAK    DAPK-related protein 
DTT     D,1-Dithiothreitol……………………………………….. 
ECL     Enhanced chemiluminescence 
EDTA    Ethylenediamine-tetra acetic acid……………………. 
EGF     Epidermal growth factor 
ELISA    Enzyme-Linked ImmunoSorbent Assay…………….. 
ERK     Extracellular regulated kinase 
FACS    Fluorescence-activated cell sorting………………….. 
FBS     Fetal bovine serum 
FCS     Fetal calf serum………………………………………... 
FITC    fluorescein isothiocyanate 
HRP     Horseradish peroxidise……………………………….. 
HSP90   Heat shock protein 90 
IFNγ    Interferon gamma……………………………………… 
Ig     Immunoglobulin 
IL     Interleukin………………………………………………. 
kDa    Kilo dalton 
JNK    c-Jun amino terminal kinase………………………….. 
Abbreviations 
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LAR Leukocyte common antigen-related tyrosine 
phasphatse 
LPS    lipopolysaccharide…………………………………….. 
M    Molarity 
MAPK    Mitogen-activated protein kinase…………………….. 
MEK     Mitogen-activated protein kinase kinase 
MLC    Myosin light chain……………………………………… 
MLCK    Myosin light chain kinase 
mRNA    Messenger ribonucleic acid…………………………... 
MSP    Methylation-specific PCR 
NF-κB    Nuclear factor-κB………………………………………. 
OD    Optical density 
PAGE    Polyacrylamid gel electrophoresis…………………… 
PDGF    Plateled-derived growth factor 
P.E.G    Polyethylenglycol 6000……………………………….. 
PI     Propidium iodide 
PMA     phorbol 12-myristate 13-acetate……………………... 
PKB     Protein kinase B 
PKD    Protein kinase D……………………………………….. 
PKC     Protein kinase C 
PMSF    Phenylmethylsulfonyl fluoride………………………… 
PS    phosphatidylserine 
RNA     Ribonucleic acid……………………………………….. 
rpm    Rotation per minute 
RPMI    Roswell Park Memorial Institute medium…………… 
RSK    Ribosomal S6 kinase 
RT-PCR   Reverse transcription polymerase chain reaction….. 
SAPK    Stress-activated protein kinase 
SDS     Sodium dodecyl sulphate……………………………... 
siRNA    Small interfering RNA 
Src     Raus sarcoma virus proto-oncogene product……….               
STAT     Signal transducers and activators of transcription 
TAM    Tumor associated macrophages…………………….. 
TBS    Tris Buffered Saline 
Abbreviations 
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TEMED    N,N,N',N'-Tetra-methylethylenediamine…………….. 
 TGFβ    Transforming growth facto beta 
 TMB    3,3′,5,5′-Tetramethylbenzidine tablets………………. 
TNFα    Tumor necrosis factor alpha 
TNFR    Tumor necrosis factor receptor………………………. 
TR    Transfection reagent 
Tris Trishydroxymethylaminomethane…………………….        
TUNEL Terminal uridine deoxynucleotidyl transferase dUTP 
nick end labeling 
WHO    World health organization…………………………….. 
ZIP    Zipper interacting protein 
ZIPK    Zipper interacting protein kinase……………………..
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